Introduction {#s2}
============

The Middle East and North Africa (MENA) region has been singled out as the region with little data and where the status of the HIV/AIDS epidemic remained unknown [@pmed.1001663-Obermeyer1]--[@pmed.1001663-Alkaiyat1]. In 2005, the region was characterized as "a real hole in terms of HIV/AIDS epidemiological data" [@pmed.1001663-Bohannon1]. The MENA region has, however, witnessed a remarkable growth in HIV research over the last decade, with several countries developing surveillance systems to monitor the spread of HIV infection, including among most-at-risk populations [@pmed.1001663-Saba1].

A large fraction of studies conducted in the region has remained unpublished in the scientific literature, and only available in the form of difficult to access country reports. This has meant that data have not been analyzed or synthesized at either country or regional level, and no critical assessment of the quality of available evidence has been conducted. The rationale for this study came from signs of a growing HIV disease burden in the MENA region, which highlighted the urgent need for a critical and comprehensive evaluation of the status of the HIV epidemic and of the quality of evidence among the different population groups to inform HIV policy and programming in the region; this was the mandate of the MENA HIV/AIDS Synthesis Project, the largest HIV study in MENA to date [@pmed.1001663-AbuRaddad1].

The present article follows on from a series of studies conducted as part of the Synthesis Project. These studies include a high-level overview of HIV epidemiology in MENA [@pmed.1001663-AbuRaddad2], a systematic review of HIV molecular evidence [@pmed.1001663-Mumtaz1], and the first documentation of the emerging HIV epidemic among men who have sex with men (MSM) in MENA [@pmed.1001663-Mumtaz2]. The present study is, to our knowledge, the first systematic review and data synthesis to characterize the status of the HIV epidemic among people who inject drugs (PWID) in MENA. The presented regional analysis takes on an additional importance with the need to capture the volume of bio-behavioral surveillance data that became available within the last few years in MENA, and is yet to be analyzed and synthesized within a country-specific or a regional context [@pmed.1001663-Mumtaz3].

PWID are one of the key populations at high risk of HIV in MENA, a region with several vulnerability factors for injecting drug use. For example, 83% of the global supply of heroin is produced in Afghanistan [@pmed.1001663-UNODC1], and over 75% of this is trafficked through Iran and Pakistan. In 2009, Iran bore the highest fraction of the global opium and heroin seizures (89% and 33%, respectively) [@pmed.1001663-UNODC1]. Increased availability and purity of heroin at lower prices in MENA appears to have led to a subsequent rise in injecting drug use [@pmed.1001663-Beyrer1]. In 2010, one gram of heroin in Afghanistan could be purchased for about US\$4 compared with up to US\$100 in West and Central Europe, US\$200 in the United States and Northern Europe, and US\$370 in Australia [@pmed.1001663-UNODC1]. Most PWID in the region are young adults and marginalized by family members and society; they are stigmatized and lack access to comprehensive and confidential HIV prevention and treatment services [@pmed.1001663-AbuRaddad1].

The primary objective of this study was to assess the status of the HIV epidemic among PWID in MENA by describing HIV prevalence and incidence. The secondary objective was to describe the risk behavior environment and the HIV epidemic potential among PWID by describing (1) their injecting and sexual risk behavior and knowledge, and (2) prevalence of proxy biological markers of these behaviors, namely hepatitis C virus (HCV) and sexually transmitted infections (STIs), respectively. The study also estimated the proportion and number of PWID in MENA.

Methods {#s3}
=======

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) ([Text S1](#pmed.1001663.s008){ref-type="supplementary-material"}) [@pmed.1001663-Moher1],[@pmed.1001663-Liberati1] and Cochrane Collaboration guidelines [@pmed.1001663-The1].

Data Sources and Search Strategy {#s3a}
--------------------------------

Our review covered the 23 countries included in the MENA definitions of the three international organizations leading the regional HIV response efforts in the region: the Joint United Nations Programme on HIV/AIDS (UNAIDS), the Eastern Mediterranean Regional Office of the World Health Organization (WHO/EMRO), and the World Bank ([Figure 1](#pmed-1001663-g001){ref-type="fig"}). These countries share specific similarities, whether historical, socio-cultural, or linguistic; and are conventionally included together as part of HIV/AIDS programming for the region.
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The following sources of data were searched up to December 16, 2013: (1) Scientific databases (PubMed, Embase, and regional databases \[WHO African Index Medicus [@pmed.1001663-World1] and WHO Index Medicus for the Eastern Mediterranean Region [@pmed.1001663-World2]\]), with no publication date or language restrictions. A generic search of "drug use" in MENA was performed in PubMed and Embase using MeSH/Emtree and text terms. The term "HIV" was not included to avoid detection bias. (2) The MENA HIV/AIDS Synthesis Project database of grey and mainly unpublished literature [@pmed.1001663-AbuRaddad1],[@pmed.1001663-AbuRaddad2]. (3) Abstracts of the International AIDS Conference 2002--2012 [@pmed.1001663-International1], the International AIDS Society Conference on HIV Pathogenesis and Treatment 2001--2013 [@pmed.1001663-International2], and the International Society for Sexually Transmitted Diseases Research Conferences 2003--2013 [@pmed.1001663-International3]. (4) International and regional databases of HIV prevalence measures including the US Census Bureau database of HIV/AIDS [@pmed.1001663-US1], the WHO/EMRO HIV testing database [@pmed.1001663-WHOEMRO1], and the UNAIDS epidemiological fact sheets database [@pmed.1001663-UNAIDS2].

Details of the search criteria are provided in [Text S2](#pmed.1001663.s009){ref-type="supplementary-material"}. Reference lists of all relevant papers and review articles were also searched.

Study Selection {#s3b}
---------------

Titles and abstracts of all records identified were screened independently by two authors (GRM and SR), and consensus on potential eligibility reached. Full texts of potentially relevant records were retrieved and assessed for eligibility. Studies satisfying any of the below criteria were eligible: (1) The proportion of PWID in the sample was specified, at least half were PWID, and data on any of the following outcomes were included: Prevalence or incidence of HIV; prevalence of injecting or sexual risk behaviors, or knowledge; prevalence or incidence of HCV; and prevalence or incidence of other STIs. HCV is transmitted primarily through percutaneous exposures and can be used as a proxy of the risk of parenteral exposure to HIV. Among PWID, a threshold HCV prevalence of about 30% implies sufficient risk behavior to sustain HIV transmission [@pmed.1001663-Vickerman1],[@pmed.1001663-Vickerman2]. Similarly, the prevalence of STIs is a useful marker of sexual risk behavior and potential for HIV sexual acquisition. (2) Data on population-based prevalence of injecting drug use or PWID population size estimates were reported.

Only studies with primary data were included. The only exception was in relation to national estimates of the number and proportion of PWID in a number of MENA countries where the only available source of data was from two global reviews [@pmed.1001663-Aceijas2],[@pmed.1001663-Mathers1] that published data compiled through the Reference Group to the UN on HIV and Injecting Drug Use [@pmed.1001663-IDU1].

We used the term report to refer to the documents (papers, conference abstracts, or public health reports) presenting findings of a study [@pmed.1001663-The1]. Reports could contribute to more than one outcome. Findings duplicated in more than one report were included only once (using the more detailed report). Outcomes in more than one population/setting within a report were included separately.

Data Extraction {#s3c}
---------------

Data were extracted by one of the authors (GRM) using a pre-piloted data extraction form and entered into a computerized database. Double extraction on about 45% of records was confirmed by another author (LA-R). The few discrepancies were settled by consensus or by contacting authors. Data from articles in English, French, and Arabic were extracted from the full -texts. Data from records in Farsi (*n* = 6) were extracted from the English abstract. There were no records in other languages.

As supporting information, we also analyzed data extracted from countries\' reporting on the HIV epidemic to WHO/EMRO in the format of aggregate HIV case notifications.

Scope and Quality of the Evidence {#s3d}
---------------------------------

We appraised the status of the evidence on our main outcome, HIV prevalence, at country level by examining the following criteria that take into consideration the quantity, quality, and geographical coverage of available data: (1) the number of HIV prevalence measures and the total sample size they cover, (2) the number of geographic settings with HIV prevalence measures, (3) the number of multi-city studies and the maximum number of cities per study, (4) the number of rounds of integrated bio-behavioral surveillance surveys (IBBSS), and (5) the quality and precision of individual HIV prevalence measures.

The quality of individual HIV prevalence measures was assessed by describing the risk of bias (ROB). Since the number of prevalence measures among female PWID was very small and often based on small sub-samples, the quality appraisal was restricted to HIV prevalence among predominantly male PWID. Based on the Cochrane approach for assessing ROB [@pmed.1001663-The1], we classified each HIV prevalence measure as having a low, high, or unclear ROB for three quality domains: the sampling methodology, the type of HIV ascertainment, and the response rate. Low ROB was considered if (1) sampling was probability-based or preceded by ethnographic mapping, (2) HIV was ascertained with a biological assay, and (3) the response rate was over 80%; or over 80% of the target sample size was reached. HIV prevalence measures extracted from international and regional databases were considered of unknown quality since original reports were not available for assessing their ROB.

A minimum sample size of 100 was considered to produce estimates with good precision. For a median HIV prevalence among PWID in MENA of 8% (see [Results](#s4){ref-type="sec"}), this implies a 95% CI of 4%--15%.

The quality of the evidence in each country was assessed by combining the above factors as described in [Text S3](#pmed.1001663.s010){ref-type="supplementary-material"}. For example, quality was considered better if at least one round of IBBSS was conducted, since these surveys use standard methodology including state of the art sampling techniques of hard-to-reach populations (such as respondent-driven sampling). Countries were categorized as having: (1) No evidence: virtually no data. (2) Poor evidence: The majority of HIV biological measures were of poor quality. (3) Limited evidence: The number of HIV biological measures was small, but of reasonable quality. (4) Good evidence: The number of HIV biological measures was small, but with good quality and informative data. However, the overall volume of data was not sufficient to be conclusive of the status and scale of the epidemic at the national level. (5) Conclusive evidence: There was a sufficient volume of robust evidence to support the conclusion.

Analysis {#s3e}
--------

The low-bound, middle, and high-bound national estimates of the number and prevalence of injecting drug use in MENA countries were extracted from reports. The pooled number and prevalence of PWID for the MENA region were estimated separately using the extracted country-level estimates. The lower (and upper) bound of our pooled regional estimate of the number of PWID in MENA was calculated by adding the lowest (and highest) reported number of PWID in all MENA countries. The middle figure for the number of PWID in MENA is the sum of the middle estimates in each of the MENA countries. When more than one such estimate was available per country, we used the median of the estimates. The pooled numbers of PWID were rounded up to the next thousand.

Middle estimates of the extracted prevalence of PWID were weighted by adult population size to derive the pooled prevalence of injecting drug use in MENA. When more than one such estimate was available per country, we used the median of the estimates. Adult population size was extracted from the United Nations World Population Database [@pmed.1001663-United1]. Sub-national estimates of the number and prevalence of injecting drug use were extracted from reports and described separately.

We calculated 95% CI for HIV and HCV prevalence for all reports with available information. The HIV biological data (HIV prevalence from reports and from databases, HIV incidence, and notified HIV cases) were synthesized at country level to assess the status of the HIV epidemic among PWID. Recent WHO/UNAIDS guidelines for classifying HIV epidemics [@pmed.1001663-UNAIDSWHO1],[@pmed.1001663-Wilson1], which do not recommend use of rigid thresholds [@pmed.1001663-UNAIDSWHO1],[@pmed.1001663-UNAIDSWHO2], were adapted to classify the HIV epidemic level in PWID as: (1) Low-level HIV epidemic: HIV has not reached significant levels among PWID. (2) Concentrated HIV epidemic: HIV has reached significant levels and taken root among PWID through transmission chains between members of this population. Concentrated epidemics can be either emerging (HIV has started its initial growth and continues in a trend of increasing HIV prevalence); or established (the epidemic has reached its peak and HIV prevalence is stabilizing towards, or already is at, its endemic level). (3) "At least outbreak-type": Insufficient evidence to support a concentrated epidemic among PWID, but some evidence, usually of lower quality, suggesting that significant HIV transmission has occurred, or is occurring, among at least some PWID groups.

The terms "national" or "at least localized" were assigned to concentrated epidemics to reflect the geographical spread of the epidemic within a given country.

Results {#s4}
=======

Results of Search Strategy {#s4a}
--------------------------

The study selection process is shown in [Figure 2](#pmed-1001663-g002){ref-type="fig"}. A total of 6,207 citations were retrieved from PubMed, Embase, and the regional databases. After full-text screening and including reports from the other sources, 192 reports were eligible: 121 from PubMed and Embase, 41 from the MENA HIV/AIDS Synthesis Project, 13 from bibliographies of relevant reports and review articles, 13 from the search of scientific conferences, and four from the regional databases. In addition, 226 HIV point-prevalence measures were extracted from the databases of biological markers ([Figure 2](#pmed-1001663-g002){ref-type="fig"}).

![PRISMA flow chart of study selection in the systematic search.](pmed.1001663.g002){#pmed-1001663-g002}

There were 423 HIV prevalence measures, 197 of which were extracted from the eligible reports and 226 from the databases of HIV prevalence; three HIV incidence measures; 93 HCV prevalence measures; four HCV incidence measures; 38 STI prevalence measures; and 993 behavioral and knowledge measures. There were also 130 and 96 measures on the number and proportion of PWID, respectively ([Figure 2](#pmed-1001663-g002){ref-type="fig"}).

Scope and Quality of the Evidence {#s4b}
---------------------------------

The number and quality of HIV prevalence measures varied by country. The largest volume of data was from Pakistan (101 HIV prevalence measures on a total of 24,445 PWID), Iran (99 HIV prevalence measures on a total of 22,181 PWID), and Egypt (39 HIV prevalence measures on a total of 4,480 PWID) ([Table 1](#pmed-1001663-t001){ref-type="table"}). A smaller number of HIV prevalence measures but covering a relatively large number of PWID were conducted in Afghanistan (3,277 PWID), Tunisia (1,522 PWID), and Morocco (880 PWID). Multi-city studies have been conducted in several countries including Pakistan, where up to 16 cities were included in one study [@pmed.1001663-Pakistan1]. IBBSS have been conducted in Afghanistan [@pmed.1001663-Afghanistan1],[@pmed.1001663-Afghanistan2], Egypt [@pmed.1001663-Family1]--[@pmed.1001663-Family2], Iran [@pmed.1001663-Iran1],[@pmed.1001663-Iran2], Jordan [@pmed.1001663-Jordan1], Lebanon [@pmed.1001663-Mahfoud1], Libya [@pmed.1001663-Mirzoyan1], Morocco [@pmed.1001663-Kingdom1], Occupied Palestinian Territories (OPT) [@pmed.1001663-Palestine1], Pakistan [@pmed.1001663-Pakistan1],[@pmed.1001663-Pakistan2]--[@pmed.1001663-Pakistan4], and Tunisia ([Table 1](#pmed-1001663-t001){ref-type="table"}) [@pmed.1001663-Tunisia1],[@pmed.1001663-Tunisia2]. Pakistan has the most repeated rounds of IBBSS with four rounds conducted between 2005 and 2011 [@pmed.1001663-Pakistan1],[@pmed.1001663-Pakistan2]--[@pmed.1001663-Pakistan4].

10.1371/journal.pmed.1001663.t001

###### Summary of the HIV biological evidence per country.

![](pmed.1001663.t001){#pmed-1001663-t001-1}

  Biological Evidence                                                                             Afg       Alg     Bah     Dji      Egy          Irn       Irq     Jor     Kuw     Leb       Lib       Mor       Oma       OPT          Pak        Qat   SA    Som   Sud     Syr        Tun      UAE   Yem
  ------------------------------------------------------------------------------------------- ------------ ----- --------- ----- ----------- ------------- ----- --------- ----- --------- --------- --------- --------- --------- --------------- ----- ----- ----- ----- --------- ----------- ----- -----
  **Number HIV biological studies** [a](#nt101){ref-type="table-fn"}                               5        ---      1      ---       7           47        ---      1      ---      2         1         3         1         1           27         ---   ---   ---   ---      1          2       ---   ---
  **Number HIV prevalence measures**                                                               19       ---     23       6       39           99         7      13      17       8         4        21        17         4           101        ---    7    ---    1      22         10       ---    5
  **From reports (total sample size)**                                                         13 (3,277)   ---   1 (242)   ---   9 (4,480)   78 (22,181)   ---   3 (227)   ---   2 (121)   1 (328)   5 (880)   3 (135)   1 (199)   *77* (24,445)   ---   ---   ---   ---   1 (204)   3 (1,522)   ---   ---
  **From databases**                                                                               6        ---     22       6       30           21         7      10      17       6         3        16        14         3          *24*        ---    7    ---    1      21          7       ---    5
  **Number HIV incidence measures** [a](#nt101){ref-type="table-fn"}                               1        ---             ---      ---           1        ---     ---     ---     ---       ---       ---       ---                     1         ---   ---   ---   ---     ---        ---      ---   ---
  **Number cities/provinces with HIV prevalence measures** [a](#nt101){ref-type="table-fn"}        6        ---      1      ---       2           27        ---      3      ---      1         1         4         1         1           26         ---   ---   ---   ---      1          3       ---   ---
  **Number multi-city studies (max number cities/study)** [a](#nt101){ref-type="table-fn"}       3 (5)      ---     ---     ---     1 (2)       4 (10)      ---    1 (4)    ---     ---       ---      2 (2)      ---       ---        12 (16)      ---   ---   ---   ---     ---       2 (3)     ---   ---
  **Number repeated IBBSS** [a](#nt101){ref-type="table-fn"}                                       2        ---     ---     ---       2            2        ---      1      ---      1         1         1        ---        1            4         ---   ---   ---   ---     ---         2       ---   ---

With reports available.

Afg, Afghanistan; Alg, Algeria; Bah, Bahrain; Dji, Djibouti; Egy, Egypt; Irn, Iran; Irq, Iraq; Jor, Jordan; Kuw, Kuwait; Leb, Lebanon; Lib, Libya; Mor, Morocco; Oma, Oman; Pak, Pakistan; QA, Qatar; SA, Saudi Arabia; Som, Somalia; Sud, Sudan; Syr, Syria; Tun, Tunisia; UAE, United Arab Emirates; Yem, Yemen.

Of 190 HIV prevalence measures extracted from eligible reports and among predominantly male PWID, 98%, 53%, and 34% had low ROB in terms of HIV ascertainment, sampling methodology, and response rate, respectively. Over 60% of the 190 HIV prevalence measures had low ROB in at least two quality domains and 84% had good precision ([Tables S1](#pmed.1001663.s001){ref-type="supplementary-material"} and [S2](#pmed.1001663.s002){ref-type="supplementary-material"}).

On the basis of the quality of the evidence assessment, the evidence was determined to be "conclusive" in Iran and Pakistan; "good" in Afghanistan, Egypt, Jordan, Lebanon, Libya, Morocco, OPT, and Tunisia; "limited" in Bahrain and Syria; and "poor" in Djibouti, Iraq, Kuwait, Oman, Saudi Arabia, Sudan, and Yemen. There was "no evidence" in Algeria, Qatar, Somalia, and the United Arab Emirates. A narrative justification for the classification of the scope and quality of evidence is in [Text S3](#pmed.1001663.s010){ref-type="supplementary-material"}.

Although a formal quality assessment was not made for the secondary outcomes in terms of injecting and sexual risk behavior and knowledge, the majority of these data were extracted from the IBBSS studies using standard survey methodology and large samples. Details of these studies (with information on sample size, population characteristics, and/or sampling technique) can be found in the tables summarizing the prevalence of HIV and HCV among PWID ([Tables 3](#pmed-1001663-t003){ref-type="table"} and [6](#pmed-1001663-t006){ref-type="table"}).

Prevalence of Injecting Drug Use {#s4c}
--------------------------------

[Table 2](#pmed-1001663-t002){ref-type="table"} describes national estimates of the number and prevalence of PWID. These national estimates were extracted from included reports where they were derived using different methodologies including indirect methods (such as capture-recapture and multiplier methods), population-based surveys, registered number of PWID, and rapid assessments. In two of the sources of data in [Table 2](#pmed-1001663-t002){ref-type="table"} [@pmed.1001663-Aceijas2],[@pmed.1001663-Mathers1], some of the country estimates are the collation of several such country-specific estimates using methods described in the original reports [@pmed.1001663-Aceijas2],[@pmed.1001663-Mathers1].

10.1371/journal.pmed.1001663.t002

###### National estimates of the number and prevalence of people who inject drugs in the Middle East and North Africa as extracted from included reports.

![](pmed.1001663.t002){#pmed-1001663-t002-2}

  Country             Population 15--64 Years [@pmed.1001663-United1]           Year of Estimate           PWID Estimate (Number)   PWID Prevalence (%)   Source                        
  ------------------ ------------------------------------------------- ---------------------------------- ------------------------ --------------------- --------- ------ ------ ------ ------------------------------
  **Afghanistan**                       16,119,000                      [a](#nt103){ref-type="table-fn"}           22,720                 34,080          45,440    0.16   0.24   0.32     [@pmed.1001663-Aceijas2]
                                                                                      2005                         6,870                   6,900           6,930    0.05   0.05   0.05     [@pmed.1001663-Mathers1]
                                                                                      2009                         18,000                 20,000          23,000                         [@pmed.1001663-Afghanistan3]
                                                                                      2009                                                                                 0.11             [@pmed.1001663-UNODC2]
  **Algeria**                           24,246,000                      [a](#nt103){ref-type="table-fn"}           26,333                 40,961          55,590    0.14   0.22   0.29     [@pmed.1001663-Aceijas2]
  **Bahrain**                             983,000                       [a](#nt103){ref-type="table-fn"}            337                     674            1,011    0.08   0.16   0.24     [@pmed.1001663-Aceijas2]
  **Djibouti**                                                                        ---                           ---                     ---             ---     ---    ---    ---                ---
  **Egypt**                             51,460,000                      [a](#nt103){ref-type="table-fn"}           56,970                 88,618          120,265   0.13   0.21   0.28     [@pmed.1001663-Aceijas2]
  **Iran**                              53,132,000                      [a](#nt103){ref-type="table-fn"}           70,000                 185,000         300,000   0.17   0.46   0.74     [@pmed.1001663-Aceijas2]
                                                                                      2004                                                180,000                          0.40            [@pmed.1001663-Mathers1]
                                                                                      2007                                                250,000                                           [@pmed.1001663-World3]
  **Iraq**                              16,967,000                      [a](#nt103){ref-type="table-fn"}           23,115                 34,673          46,230    0.19   0.28   0.37     [@pmed.1001663-Aceijas2]
  **Jordan**                             3,624,000                      [a](#nt103){ref-type="table-fn"}           3,200                   4,850           6,500    0.11   0.16   0.22     [@pmed.1001663-Aceijas2]
  **Kuwait**                             1,937,000                      [a](#nt103){ref-type="table-fn"}           2,700                   4,100           5,500    0.20   0.30   0.41     [@pmed.1001663-Aceijas2]
  **Lebanon**                            2,871,000                      [a](#nt103){ref-type="table-fn"}           2,200                   3,300           4,400    0.09   0.14   0.19     [@pmed.1001663-Aceijas2]
  **Libya**                              4,148,000                      [a](#nt103){ref-type="table-fn"}           4,633                   7,206           9,779    0.15   0.23   0.32     [@pmed.1001663-Aceijas2]
                                                                                      2001                                                 1,685                           0.05            [@pmed.1001663-Mathers1]
  **Morocco**                           21,247,000                      [a](#nt103){ref-type="table-fn"}                                  18,500                           0.10            [@pmed.1001663-Aceijas2]
  **Oman**                               1,956,000                      [a](#nt103){ref-type="table-fn"}           2,800                   4,250           5,700    0.20   0.30   0.40     [@pmed.1001663-Aceijas2]
  **OPT**                                2,212,000                      [a](#nt103){ref-type="table-fn"}           1,200                   1,850           2,500    0.22   0.35   0.47     [@pmed.1001663-Aceijas2]
  **Pakistan**                          104,724,000                     [a](#nt103){ref-type="table-fn"}           54,000                 462,000         870,000   0.07   0.50   1.12     [@pmed.1001663-Aceijas2]
                                                                                      2006                        125,000                 130,460         150,000   0.13   0.14   0.16     [@pmed.1001663-Mathers1]
                                                                                      2006                                                102,042                          0.25           [@pmed.1001663-Emmanuel1]
                                                                                      2010                                                99,000                                            [@pmed.1001663-World3]
  **Qatar**                              1,503,000                      [a](#nt103){ref-type="table-fn"}            780                    1,190           1,600    0.15   0.22   0.30     [@pmed.1001663-Aceijas2]
  **Saudi Arabia**                      18,306,000                      [a](#nt103){ref-type="table-fn"}           15,172                 23,600          32,028    0.13   0.20   0.27     [@pmed.1001663-Aceijas2]
                                                                                      2008                                                10,000                                            [@pmed.1001663-World3]
  **Somalia**                            4,885,000                      [a](#nt103){ref-type="table-fn"}                                   1,000                           0.03            [@pmed.1001663-Aceijas2]
  **Sudan**                             24,540,000                      [a](#nt103){ref-type="table-fn"}           24,319                 37,828          51,337    0.13   0.20   0.28     [@pmed.1001663-Aceijas2]
  **Syria**                             12,073,000                      [a](#nt103){ref-type="table-fn"}           4,000                   6,000           8,000    0.04   0.07   0.09     [@pmed.1001663-Aceijas2]
  **Tunisia**                            7,294,000                      [a](#nt103){ref-type="table-fn"}           8,462                  13,163          17,864    0.14   0.21   0.29     [@pmed.1001663-Aceijas2]
                                                                                      2009                                                 9,000                                            [@pmed.1001663-World3]
  **UAE**                                6,200,000                      [a](#nt103){ref-type="table-fn"}           3,200                   4,800           6,400    0.20   0.30   0.40     [@pmed.1001663-Aceijas2]
  **Yemen**                             12,800,000                      [a](#nt103){ref-type="table-fn"}           12,710                 19,770          26,830    0.15   0.23   0.31     [@pmed.1001663-Aceijas2]

The specific year of the estimate was not mentioned in the original report, but the report covered data from 1998--2005.

UAE, United Arab Emirates.

Based on available data, the number of PWID in MENA ranges between a low bound of 335,000 and a high bound of 1,635,000, with a middle estimate of 626,000 PWID. Iran, Pakistan, and Egypt have the largest number, with a median of about 185,000, 117,000, and 89,000 PWID, respectively. The weighted mean prevalence of injecting drug use in MENA is 0.24 per 100 adults. It is lowest in Somalia (0.03%) and highest in Iran (0.43%) ([Table 2](#pmed-1001663-t002){ref-type="table"}).

Studies of sub-national populations showed geographical heterogeneity ([Table S3](#pmed.1001663.s003){ref-type="supplementary-material"}). For example, in Iran, the prevalence of injecting drug use varied between 0.0% in rural Babol province [@pmed.1001663-Meysamie1] to 1.0% in Tehran [@pmed.1001663-Merat1]; and in Pakistan it ranged from 0.02% in Rawalpindi to 0.87% and 1.07% in Sargodha and Faisalabad, respectively [@pmed.1001663-Emmanuel1].

Data on the prevalence of female PWID in MENA were scarce. Overall, the mean proportion of females among PWID in included studies was 2.3% (range: 0%--35%). In two studies in Oman and Syria, 25%--58% [@pmed.1001663-Oman1] and 48% [@pmed.1001663-Syria1] of PWID, respectively, reported knowing at least one female PWID.

HIV Prevalence, Incidence, and Mode of Transmission {#s4d}
---------------------------------------------------

HIV prevalence measures from reports and databases are summarized in [Tables 3](#pmed-1001663-t003){ref-type="table"} and [S4](#pmed.1001663.s004){ref-type="supplementary-material"}, respectively. Considerable variation in HIV prevalence was seen, with an overall median of 8% (interquartile range \[IQR\]: 1%--21%) ([Table 3](#pmed-1001663-t003){ref-type="table"}). HIV prevalence among PWID in MENA ranged between 0% in some prevalence measures in almost every country up to 7% in Cairo, Egypt in 2010 (*n* = 274) [@pmed.1001663-Family2]; 18% in Afghanistan in one city near the Iranian borders, Herat, in 2009 (*n* = 159) [@pmed.1001663-Afghanistan1]; 21% in Manama, Bahrain, in the early nineties (*n* = 242) [@pmed.1001663-AlHaddad1]; 27% in Oman among incarcerated PWID (*n* = 33) [@pmed.1001663-Oman1]; 38% in Nador, northern Morocco, in 2008 (*n* = 233) [@pmed.1001663-Morocco1]; 52% in the third largest metropolis in Pakistan, Faisalabad, in 2011 (*n* = 364) [@pmed.1001663-Pakistan1]; 72% in rural Iran in 2004--5 (*n* = 61) [@pmed.1001663-Mojtahedzadeh1]; and 87% in Tripoli, Libya in 2010 (*n* = 328) [@pmed.1001663-Mirzoyan1] ([Table 3](#pmed-1001663-t003){ref-type="table"}). HIV prevalence was consistently low among PWID in Jordan, Lebanon, OPT, Syria, and Tunisia (0%--3.1%). Substantial intra-country variability in HIV prevalence was observed in Afghanistan, Iran, Morocco, and Pakistan ([Table 3](#pmed-1001663-t003){ref-type="table"}). In most countries with high HIV prevalence, recent studies report increasing HIV prevalence starting around 2003 ([Tables 3](#pmed-1001663-t003){ref-type="table"} and [S4](#pmed.1001663.s004){ref-type="supplementary-material"}).

10.1371/journal.pmed.1001663.t003

###### HIV prevalence among people who inject drugs in the Middle East and North Africa as extracted from reports included in the systematic review.

![](pmed.1001663.t003){#pmed-1001663-t003-3}

  Country                                   Citation                             Year                         City                                                     Study Site                                  Sampling               Population                            Sample Size                          HIV Prevalence             
  ----------------- -------------------------------------------------------- ------------ -------------------------------------------- -------------------------------------------------------------------------- ---------- ------------------------------------- ------------------------------------- -------------------------------------- --------------------------------------------
  **Afghanistan**      MOH, 2012 [@pmed.1001663-Afghanistan2] (Round II)         2012                        Herat                                                                                                   RDS                   All male                                 185                   13.3[a](#nt105){ref-type="table-fn"}                   8.9--19.3
                                                                                                             Kabul                                                                                                   RDS                   All male                                 369                   2.4[a](#nt105){ref-type="table-fn"}                     1.1--4.6
                                                                                                         Mazar-i-Sharif                                                                                              RDS                   All male                                 254                   0.3[a](#nt105){ref-type="table-fn"}                     0.0--2.2
                                                                                                           Jalalabad                                                                                                 RDS                   All male                                 236                   1.0[a](#nt105){ref-type="table-fn"}                     0.1--3.0
                                                                                                            Charikar                                                                                                 RDS                   All male                                 117                   0.9[a](#nt105){ref-type="table-fn"}                     0.0--4.7
                        MOH, 2010 [@pmed.1001663-Afghanistan1] (Round I)         2009                        Herat                                                                                                   RDS                   All male                                 159                                   18.2                                   12.6--25.1
                                                                                                             Kabul                                                                                                   RDS                   All male                                 286                                   3.2                                     1.4--5.9
                                                                                                         Mazar-i-Sharif                                                                                              RDS                   All male                                 102                                   1.0                                     0.0--5.3
                                Todd, 2011 [@pmed.1001663-Todd2]              2007--2009                     Kabul                                         Harm reduction center & community                          CS                   All male                                 483                                   2.1                                     1.0--3.8
                               Nasir, 2011 [@pmed.1001663-Nasir1]             2006--2008                     Herat                                                        VCT                                         CS                   99% male                                 340                                   3.2                                     1.6--5.7
                                                                                                           Jalalabad                                                      VCT                                         CS                   99% male                                 96                                    0.0                                       ---
                                                                                                         Mazar-i-Sharif                                                   VCT                                         CS                   99% male                                 187                                   0.0                                       ---
                                Todd, 2007 [@pmed.1001663-Todd5]              2005--2006                     Kabul                                                        VCT                                         CS                   All male                                 463                                   3.0                                     1.7--5.0
  **Bahrain**              Al-Haddad, 1994 [@pmed.1001663-AlHaddad1]             1991                        Manama                                         Voluntary drug treatment center                           CS                   All male                                 242                                   21.1                                   16.1--26.8
  **Egypt**             MOH/FHI, 2010 [@pmed.1001663-Family2] (Round II)         2010                      Alexandria                                                                                                RDS                   All male                                 284                   6.5[a](#nt105){ref-type="table-fn"}    3.3--10.3[a](#nt105){ref-type="table-fn"}
                                                                                                             Cairo                                                                                                   RDS                   All male                                 274                   6.8[a](#nt105){ref-type="table-fn"}    3.9--10.8[a](#nt105){ref-type="table-fn"}
                          Elghamrawy, 2012 [@pmed.1001663-Elghamrawy1]        2008--2011                     Cairo                                               Harm reduction center                                CS                   All male                                3,222                                  1.4                                     1.0--1.9
                        Soliman, 2010 [@pmed.1001663-Soliman1] (Round I)         2006                        Cairo                                                                                                   RDS                   All male                                 413                   0.6[a](#nt105){ref-type="table-fn"}     0.1--1.8[a](#nt105){ref-type="table-fn"}
                        MOH/FHI, 2006 [@pmed.1001663-Family1] (Round I)          2006                        Cairo                                                                                                   RDS                  All female                                16                                    0.0                                       ---
                               Saleh, 1998 [@pmed.1001663-Saleh1]                1994                      Alexandria                                       Voluntary drug treatment center                           CS                                                            100                                   0.0                                       ---
                               Attia, 1996 [@pmed.1001663-Attia1]                ---                       Alexandria                                       Voluntary drug treatment center                           CS                                                            54                                    0.0                                       ---
                               Hasan, 1994 [@pmed.1001663-Hasan1]                ---                                                                                                                                  CS                                                            79                                    7.6                                    2.8--15.8
                         El-Ghazzawi, 1987 [@pmed.1001663-ElGhazzawi1]           ---                       Alexandria                                                                                                 CS                                                            38                                    0.0                                       ---
  **Iran**                  Honarvar, 2013 [@pmed.1001663-Honarvar1]          2012--2013                     Shiraz                                         Voluntary drug treatment center                           CS                   98% male                                 233                                   7.7                                    4.6--11.9
                          Mehrejredi, 2013 [@pmed.1001663-Mehrjerdi1]            2011                        Tehran                                          VCT and harm reduction center                            CS                   91% male                                 209                                   2.9                                     1.1--6.1
                           MOH, 2010 [@pmed.1001663-Iran2] (Round II)            2010                         Fars                      VCT, Harm reduction center, voluntary drug treatment center, & community      CS                   98% male                                 250                                   31.9                                   26.3--38.2
                                                                                                            Lorestan                                                      Idem                                        CS                   All male                                 222                                   26.4                                   20.9--32.9
                                                                                                             Tehran                                                       Idem                                        CS                   95% male                                 567                                   23.9                                   20.5--27.7
                                                                                                      Sistan & Baluchestan                                                Idem                                        CS                   99% male                                 138                                   18.3                                   12.1--25.6
                                                                                                           Kermanshah                                                     Idem                                        CS                   99% male                                 249                                   16.8                                   12.4--22.1
                                                                                                           Khouzestan                                                     Idem                                        CS                   99% male                                 198                                   9.4                                    5.9--14.6
                                                                                                           Mazandaran                                                     Idem                                        CS                   97% male                                 276                                   7.0                                    4.2--10.5
                                                                                                             Kerman                                                       Idem                                        CS                   94% male                                 213                                   6.2                                    3.3--10.2
                                                                                                       Azerbaijan Sharghi                                                 Idem                                        CS                   100% male                                118                                   3.6                                     0.9--8.5
                                                                                                        Khorasan Razavi                                                   Idem                                        CS                   99% male                                 248                                   2.2                                     0.7--4.6
                             Alipour, 2012 [@pmed.1001663-Alipour1]              2010              Tehran, Shiraz, & mashhad                                     Harm reduction center                                CS        All male, heterosexually active                     226                                   9.4                                    5.8--13.9
                                                                                                   Tehran, Shiraz, & mashhad                                     Harm reduction center                                CS      All female, sexual partners of PWID                   42                                    7.7                                    1.5--19.5
                               Ilami, 2010 [@pmed.1001663-Ilami1]             2009--2010            Kohgiloyeh & Boyerahmad                                                                                           CS                                                            158                                   9.9                                    5.9--15.9
                         Hashemepour, 2013 [@pmed.1001663-Hashemipour1]          2009                    North Isfahan                                                 Community                                      CS                                                            82                                    1.2                                     0.0--6.6
                                                                                                         South Isfahan                                                 Community                                      CS                                                            589                                   1.0                                     0.4--2.2
                                                                                                          West Isfahan                                                 Community                                      CS                                                            479                                   1.7                                     0.7--3.3
                                                                                                          East Isfahan                                                 Community                                      CS                                                            113                                   3.5                                     1.0--8.8
                                                                                                          Isfahan city                                                 Community                                      CS                                                            336                                   1.5                                     0.5--3.4
                               Dibaj, 2013 [@pmed.1001663-Dibaj1]             2008--2009                    Isfahan                                                      Prison                                       CS                   All male                                 970                                   6.4                                     4.9--8.1
                              Javadi, 2013 [@pmed.1001663-Javadi1]            2008--2009                    Isfahan                                              Harm reduction center                                CS                   95% male                                 539                                   1.1                                     0.4--2.4
                         Eskandarieh, 2013 [@pmed.1001663-Eskandarieh1]          2008                        Tehran                                         Mandatory drug treatment center                           CS                   97% male                                 258                                   18.8                                   14.4--24.3
                              Zamani, 2010 [@pmed.1001663-Zamani4]               2008                       Isfahan                                                                                                  RDS                   98% male                                 117                   0.7[a](#nt105){ref-type="table-fn"}     0·6--2.3[a](#nt105){ref-type="table-fn"}
                           Ghasemian, 2011 [@pmed.1001663-Ghasemian1]         2007--2009                      Sari                                                  Clinical setting                                  CS                                                            88                                    18.2                                   10.8--27.8
                               Zadeh, 2014 [@pmed.1001663-Zadeh1]             2007--2008                     Tehran                                                      Prison                                       CS                                                           3,044                                  3.7                                     3.1--4.4
                         SeyedAlinaghi, 2013 [@pmed.1001663-Alinaghi1]        2007--2008                     Tehran                                                    Community                                      CS                    Beggars                                 658                                   2.4                                     1.4--3.9
                           Kazerooni, 2010 [@pmed.1001663-Kazerooni1]            2007                        Shiraz                                                      Prison                                      SRS                   All male                                 363                                   6.6                                     4.3--9.7
                           Aminzadeh, 2007 [@pmed.1001663-Aminzadeh1]            2007                        Tehran                                                 Clinical setting                                  CS                                                            70                                    30.0                                   19.6--42.1
                     Rahimi_Movaghar, 2010 [@pmed.1001663-RahimiMovaghar1]    2006--2007                     Tehran                                   Voluntary drug treatment center & community                     CS                  All female                                38                                    10.5                                   2.9--24.8
                                                                                                             Tehran                                   Voluntary drug treatment center & community                     CS                   All male                                 861                                   10.7                                   8.7--12.9
                         Kheirandish, 2010 [@pmed.1001663-Kheirandish1]          2006                        Tehran                                         Mandatory drug treatment center                           CS                   All male                                 459                                   24.4                                   20.5--28.6
                           MOH, 2008 [@pmed.1001663-Iran1] (Round I)          2006--2007               Azerbaijan Sharghi                 Harm reduction center, voluntary drug treatment center, & community        TLS                   96% male                                 294                                   8.2                                    5.3--11.9
                                                                                                              Fars                                                        Idem                                       TLS                   92% male                                 353                                   24.7                                   20.2--29.5
                                                                                                             Kerman                                                       Idem                                       TLS                   96% male                                 162                                   20.8                                   15.0--28.1
                                                                                                           Kermanshah                                                     Idem                                       TLS                   99% male                                 259                                   30.5                                   25.0--36.5
                                                                                                        Khorasan Razavi                                                   Idem                                       TLS                   98% male                                 399                                   6.5                                     4.3--9.4
                                                                                                           Khuzestan                                                      Idem                                       TLS                   99% male                                 168                                   4.2                                     1.7--8.4
                                                                                                            Lorestan                                                      Idem                                       TLS                   97% male                                 196                                   35.7                                   29.0--42.9
                                                                                                           Mazandaran                                                     Idem                                       TLS                   All male                                 216                                   11.6                                   7.6--16.6
                                                                                                             SIstan                                                       Idem                                       TLS                   93% male                                 142                                   2.1                                     0.4--6.0
                                                                                                             Tehran                                                       Idem                                       TLS                   98% male                                 664                                   14.4                                   11.9--17.4
                         Malekinejad, 2008 [@pmed.1001663-Malekinejad1]       2006--2007                     Tehran                                                                                                  RDS                   98% male                 548[a](#nt105){ref-type="table-fn"}                   25.0                                   18.0--28.3
                               Alavi, 2012 [@pmed.1001663-Alavi1]             2005--2006                     Ahfaz                                      Voluntary drug treatment center & prison                      CS                   All male                                 109                                   47.7                                   38.1--57.5
                        Ghanbarzadeh, 2006 [@pmed.1001663-Ghanbarzadeh1]         2005                       Birjand                                                      Prison                                       CS                  All female                                10                                    0.0                                       ---
                              Tofigi, 2011 [@pmed.1001663-Tofigi1]               2004                        Tehran                                                 Clinical setting                                  CS                   Cadavers                                 400                                   6.3                                     4.1--9.1
                               Imani, 2008 [@pmed.1001663-Imani1]                2004                     Shahr-e-Kord                                      Voluntary drug treatment center                           CS                   All male                                 133                                   0.8                                     0·0--4·1
                       Mojtahedzadeh, 2008 [@pmed.1001663-Mojtahedzadeh1]     2004--2005            Rural Northwestern Iran                                 Voluntary drug treatment center                           CS          98% male, rural population                        61                                    72.1                                   59.2--82.9
                              Zamani, 2006 [@pmed.1001663-Zamani1]               2004                        Tehran                                        Harm reduction center & community                          CS                  All female                                 6                                    33.3                                   4.3--77.7
                                                                                                             Tehran                                        Harm reduction center & community                          CS                   All male                                 207                                   23.2                                   17.6--29.5
                             Shamaei, 2009 [@pmed.1001663-Shamaei1]           2003--2006                     Tehran                                                 Clinical setting                                  CS          98% male, TB infected PWID                        35                                    45.7                                   28.8--63.4
                           Pourahmad, 2007 [@pmed.1001663-Pourahmad1]            2003      Isfahan, Chaharmahal Bakhtiary, & Lorestan                                    Prison                                       CS                   All male                                 401                                   14.0                                   10.7--17.7
                              Zamani, 2005 [@pmed.1001663-Zamani5]            2003--2004                     Tehran                                         Voluntary drug treatment center                           CS                  All female                                 5                                    20.0                                   0.5--71.6
                                                                                                             Tehran                                         Voluntary drug treatment center                           CS                   All male                                 165                                   15.2                                   10.1--21.5
                            Farhoudi, 2003 [@pmed.1001663-Farhoudi1]             2003                        Karaj                                                 Resident prisoners                                 CS          All male, resident inmates                        371                                   24.0                                   19.7--28.7
                                                                                                             Karaj                                              Newly admitted prisoners                              CS      All male, newly 7--admitted inmates                   369                                   22.0                                   17.8--26.5
                      Khodadadizadeh, 2003 [@pmed.1001663-Khodadadizadeh1]       2003                      Rafsanjan                                                Clinical setting                                  CS                   96% male                                 31                                    9.7                                    2.0--25.8
                               Alavi, 2010 [@pmed.1001663-Alavi2]             2002--2006                     Ahfaz                                                  Clinical setting                                  CS         97% male, hospitalized for ID                      333                                   18.0                                   14.6--23.2
                           Davoodian, 2009 [@pmed.1001663-Davoodian1]            2002                      Hormozgan                                                     Prison                                      SRS                                                            249                                   15.1                                   11.0--20.3
                              Behnaz, 2007 [@pmed.1001663-Behnaz1]            2002--2003                     Gorgan                                                      Prison                                      SRS                                                            22                                    18.2                                   5.2--40.3
                               Asadi, 2006 [@pmed.1001663-Asadi1]             2002--2004                     Tehran                                                 Clinical setting                                  CS                   98% male                                 126                                   35.7                                   27.4--44.7
                            Alizadeh, 2005 [@pmed.1001663-Alizadeh1]             2002                       Hamadan                                                      Prison                                      SRS                   93% male                                 149                                   0.7                                     0.0--3.7
                         Mir Nasseri, 2011 [@pmed.1001663-MirNasseri1]        2001--2002                     Tehran                                         Voluntary drug treatment center                           CS                   97% male                                 90                                    7.8                                    3·7--13·5
                                                                                                             Tehran                                                      Prison                                      SRS                   87% male                                 371                                   17.0                                   13.5--21.2
                              Sharif, 2009 [@pmed.1001663-Sharif1]            2001--2006                     Kashan                                                 Clinical setting                                  CS        All female, hospitalized for ID                     23                                    0.0                                       ---
                                                                                                             Kashan                                                 Clinical setting                                  CS         All male, hospitalized for ID                      177                                   1.6                                     0.4--4.9
                               Alavi, 2009 [@pmed.1001663-Alavi3]             2001--2006                     Ahfaz                                                  Clinical setting                                  CS                   92% male                                 142                                   12.7                                   7.7--19.3
                               Alavi, 2007 [@pmed.1001663-Alavi4]             2001--2003                     Ahfaz                                                  Clinical setting                                  CS                   All male                                 154                                   67.5                                   59.5--74.8
                              Rahbar, 2004 [@pmed.1001663-Rahbar1]            2001--2002                    Mashhad                                         Voluntary drug treatment center                           CS                                                            222                                   0.0                                       ---
                                                                                                            Mashhad                                                      Prison                                       CS                                                            101                                   6.9                                    2.8--13.8
                        Sharifi-Mood, 2006 [@pmed.1001663-SharifiMood1]       2000--2005                    Zahedan                                                 Clinical setting                                  CS         97% male, hospitalized for ID                      31                                    25.8                                   11.9--44.6
                      Mirahmadizadeh, 2004 [@pmed.1001663-Mirahmadizadeh1]       1998                        Shiraz                                         Voluntary drug treatment center                           CS                                                            464                                   1.2                                     0.5--2.8
                            Nowroozi, 1998 [@pmed.1001663-Nowroozi1]             1996                        Tehran                                                      Prison                                      SRS                   All male                                 400                                   0.0                                       ---
                             Alavian, 2013 [@pmed.1001663-Alavian1]              ---                         Shiraz                                         Voluntary drug treatment center                           CS                   98% male                                 144                                   41.7                                   33.5--50.2
                             Azarkar, 2010 [@pmed.1001663-Azarkar1]              ---                        Birjand                                                      Prison                                      SRS                                                            17                                    0.0                                       ---
                      Mirahmadizadeh, 2009 [@pmed.1001663-Mirahmadizadeh2]       ---                        National                                                    National                                     RCS                   96% male                                 936                                   20.5                                   18.0--23.2
                               Amini, 2005 [@pmed.1001663-Amini1]                ---                         Tehran                                         Voluntary drug treatment center                           CS                                                            34                                    8.8                                    1.9--23.7
                               Alaei, 2002 [@pmed.1001663-Alaei1]                ---                       Kermanshah                                                                                                 CS                                                            429                                   19.2                                   15.5--23.2
  **Jordan**              NAP, 2010 [@pmed.1001663-Jordan1] (Round I)            2009                        Amman                                                                                                   RDS                                                            133                                   0.0                                       ---
                                                                                                             Aqaba                                                                                                   RDS                                                            78                                    0.0                                       ---
                                                                                                             Irbid                                                                                                   RDS                                                            16                                    0.0                                       ---
  **Lebanon**           Mahfoud, 2010 [@pmed.1001663-Mahfoud1] (Round I)      2007--2008                     Beirut                                                                                                  RDS                   All male                                 81                                    0.0                                       ---
                               Ramia, 2003 [@pmed.1001663-Ramia1]             2000--2002                     Beirut                                                 Clinical setting                                  CS                   75% male                                 40                                    0.0                                       ---
  **Libya**            Mirzoyan, 2013 [@pmed.1001663-Mirzoyan1] (Round I)        2010                       Tripoli                                                                                                  RDS                                                            328                   87.1[a](#nt105){ref-type="table-fn"}   81.5--91.9[a](#nt105){ref-type="table-fn"}
  **Morocco**             MOH, 2012 [@pmed.1001663-Morocco2] (Round I)        2011--2002                     Nador                                                                                                   RDS                   99% male                                 277                   25.1[a](#nt105){ref-type="table-fn"}                   16.1--35.0
                          MOH, 2012 [@pmed.1001663-Morocco2] (Round I)        2010--2001                     Tanger                                                                                                  RDS                   98% male                                 261                                   0.4                                     0.0--2.1
                               MOH, 2010 [@pmed.1001663-Morocco1]                2008                      Al Hoceima                                                                                                RDS                                                                                                  0.0                                       ---
                                                                                                             Nador                                                                                                   RDS                                                            233                                   37.8                                   31.5--44.3
                              Elmir, 2002 [@pmed.1001663-Elharti1]            1991--1999                    National                                                                                                  CS                                                            109                                    33                                      24--43
  **Oman**                      MOH, 2006 [@pmed.1001663-Oman1]                  ---                         Muscat                                         Voluntary drug treatment center                           CS                   All male                                 17                     12[b](#nt106){ref-type="table-fn"}                      2--36
                                                                                 ---                         Muscat                                                      Prison                                       CS                   All male                                 33                     27[b](#nt106){ref-type="table-fn"}                      13--46
                                                                                 ---                         Muscat                                                    Community                                     SBS                   All male                                 85                     18[b](#nt106){ref-type="table-fn"}                      10--27
  **OPT**                MOH, 2010 [@pmed.1001663-Stulhofer1] (Round I)          2010              Al Azaria - East Jerusalem                                                                                        RDS                  98.5% male                                199                                   0.0                                       ---
  **Pakistan**           NAP, 2011 [@pmed.1001663-Pakistan1] (Round IV)          2011                       D G Khan                                                   Community                                     MSCS                 98.4% male                                365                                   49.6                                   44.3--54.8
                                                                                                           Faisalabad                                                  Community                                     MSCS                 98.4% male                                364                                   52.5                                   47.2--57.7
                                                                                                             Gurjat                                                    Community                                     MSCS                 98.4% male                                208                                   46.2                                   39.2--53.2
                                                                                                             Lahore                                                    Community                                     MSCS                 98.4% male                                367                                   30.8                                   26.1--35.8
                                                                                                             Multan                                                    Community                                     MSCS                 98.4% male                                365                                   24.9                                   20.6--29.7
                                                                                                           Pakpattan                                                   Community                                     MSCS                 98.4% male                                365                                   3.3                                     1.7--5.7
                                                                                                         Rahim Yar Khan                                                Community                                     MSCS                 98.4% male                                214                                   14.9                                   10.5--20.4
                                                                                                            Sarghoda                                                   Community                                     MSCS                 98.4% male                                365                                   40.6                                   35.5--45.8
                                                                                                              Dadu                                                     Community                                     MSCS                 98.4% male                                194                                   16.0                                   11.1--21.9
                                                                                                            Karachi                                                    Community                                     MSCS                 98.4% male                                365                                   42.2                                   37.1--47.4
                                                                                                            Larkana                                                    Community                                     MSCS                 98.4% male                                365                                   18.6                                   14.8--23.0
                                                                                                             Sukkur                                                    Community                                     MSCS                 98.4% male                                365                                   19.2                                   15.3--23.6
                                                                                                            Haripur                                                    Community                                     MSCS                 98.4% male                                65                                    7.9                                    2.5--17.0
                                                                                                            Peshawar                                                   Community                                     MSCS                 98.4% male                                260                                   20.0                                   15.3--25.4
                                                                                                             Quetta                                                    Community                                     MSCS                 98.4% male                                365                                   7.1                                    4.7--10.3
                                                                                                             Turbat                                                    Community                                     MSCS                 98.4% male                                365                                   21.4                                   17.3--25.9
                             Nai Zindagi, 2009 [@pmed.1001663-Nai1]              2009                      Gurjanwala                                                  Community                                      CS                                                            300                                    8                                       5--12
                                                                                                        Mandi Bahauddin                                                Community                                      CS                                                            300                                    52                                      46--58
                                                                                                           Rawalpindi                                                  Community                                      CS                                                            300                                    23                                      18--28
                                                                                                         Sheikhukupura                                                 Community                                      CS                                                            300                                    21                                      17--26
                             Nai Zindagi, 2008 [@pmed.1001663-Nai3]              2008                      Faisalabad                                                                                                 CS               All male, married                            104                                    13                                      8--22
                                                                                                             Lahore                                                                                                   CS               All male, married                            103                                    10                                      5--17
                                                                                                            Sarghoda                                                                                                  CS               All male, married                            252                                    41                                      35--47
                        NAP, 2008 [@pmed.1001663-Pakistan2] (Round III)          2008                       D G Khan                                                   Community                                     MSCS                 99.8% male                                345                                   18.6                                   14.6--23.1
                                                                                                           Faisalabad                                                  Community                                     MSCS                 99.8% male                                400                                   12.3                                   9.2--15.9
                                                                                                           Hyderabad                                                   Community                                     MSCS                 99.8% male                                397                                   30.5                                   26.0--35.3
                                                                                                            Karachi                                                    Community                                     MSCS                 99.8% male                                403                                   23.1                                   19.1--27.5
                                                                                                             Lahore                                                    Community                                     MSCS                 99.8% male                                401                                   14.5                                   11.2--18.3
                                                                                                            Larkana                                                    Community                                     MSCS                 99.8% male                                389                                   28.5                                   24.1--33.3
                                                                                                            Peshawar                                                   Community                                     MSCS                 99.8% male                                231                                   12.8                                   8.9--18.0
                                                                                                            Sarghoda                                                   Community                                     MSCS                 99.8% male                                403                                   22.8                                   18.8--27.2
                               Platt, 2009 [@pmed.1001663-Platt1]                2007                      Rawalpindi                                                                                                RDS                   98% male                                 302                                   2.6                                     1.2--5.2
                                                                                                            Abotabad                                                                                                 RDS                   98% male                                 102                                   0.0                                       ---
                      NAP, 2006--2007 [@pmed.1001663-Pakistan3] (Round II)    2006--2007                     Bannu                                                     Community                                     MSCS                                                           72                                    1.4                                     0.0--7.5
                                                                                                           Faisalabad                                                  Community                                     MSCS                                                           400                                   13.3                                   10.1--17.0
                                                                                                           Gurjanwala                                                  Community                                     MSCS                                                           400                                   1.0                                     0.3--2.5
                                                                                                           Hyderabad                                                   Community                                     MSCS                                                           400                                   29.8                                   25.3--34.5
                                                                                                            Karachi                                                    Community                                     MSCS                                                           399                                   30.1                                   25.6--34.8
                                                                                                             Lahore                                                    Community                                     MSCS                                                           400                                   6.5                                     4.3--9.4
                                                                                                            Larkana                                                    Community                                     MSCS                                                           399                                   16.5                                   13.0--20.6
                                                                                                             Multan                                                    Community                                     MSCS                                                           400                                   0.0                                       ---
                                                                                                            Peshawar                                                   Community                                     MSCS                                                           180                                   2.2                                     0.6--5.6
                                                                                                             Quetta                                                    Community                                     MSCS                                                           190                                   9.5                                    5.7--14.6
                                                                                                            Sarghoda                                                   Community                                     MSCS                                                           400                                   51.3                                   46.2--56.2
                                                                                                             Sukkur                                                    Community                                     MSCS                                                           399                                   5.3                                     3.3--7.9
                              Rahman, 2006 [@pmed.1001663-Rahman1]               2005                        Lahore                                                                                                   CS                   All male                                                                       0.0                                       ---
                             Nai zindagi, 2005 [@pmed.1001663-Nai4]              2005                      Faisalabad                                                                                                SRS                   All male                                 200                                   9.5                                    5.8--14.4
                                                                                                             Lahore                                                                                                  SRS                   All male                                 200                                   2.5                                     0.8--5.7
                                                                                                            Sarghoda                                                                                                 SRS                   All male                                 100                                   12.0                                   6.4--20.0
                                                                                                            Sialkot                                                                                                  SRS                   All male                                 100                                   1.0                                     0.0--5.4
                         NAP, 2005 [@pmed.1001663-Pakistan4] (Round I)           2005                      Faisalabad                                                  Community                                     TLS                                                            400                                   13.3                                   10.1--17.0
                                                                                                           Hyderabad                                                   Community                                     TLS                                                            398                                   25.3                                   21.2--30.0
                                                                                                             Lahore                                                    Community                                     TLS                                                            400                                   3.8                                     2.1--6.1
                                                                                                             Multan                                                    Community                                     TLS                                                            400                                   0.3                                     0.0--1.4
                                                                                                            Peshawar                                                   Community                                     TLS                                                            284                                   0.4                                     0.0--1.9
                                                                                                             Quetta                                                    Community                                     TLS                                                            147                                   9.5                                    5.3--15.5
                                                                                                             Sukkur                                                    Community                                     TLS                                                            402                                   19.2                                   15.4--23.3
                             Bokhari, 2007 [@pmed.1001663-Bokhari1]              2004                       Karachi                                                    Community                                     TLS                   All male                                 402                                   23.1                                   19.1--27.6
                                                                                                             Lahore                                                    Community                                     TLS                   All male                                 397                                   0.5                                     0.1--1.8
                            Achakzai, 2007 [@pmed.1001663-Achakzai1]             2004                        Quetta                                                    Community                                      CS                                                            50                                    24.0                                   13.1--38.2
                         Bokhari, 2006 [@pmed.1001663-Bokhari2] (Pilot)       2004--2005                    Karachi                                                                                                  TLS                                                            400                                   26.0                                   21.8--30.6
                                                                                                           Rawalpindi                                                                                                 CS                                                            199                                   0.5                                     0.0--2.8
                              Abbasi, 2005 [@pmed.1001663-Abbasi1]               2004                       Larkana                                                       VCT                                         CS              All male, homeless                           3154                                   8.3                                     7.4--9.3
                              Abbasi, 2009 [@pmed.1001663-Abbasi2]               2003                        Quetta                                         Voluntary drug treatment center                           CS                   All male                                 300                                   0.3                                     0.0--1.8
                               Altaf, 2007 [@pmed.1001663-Altaf1]                2003                       Karachi                                              Harm reduction center                                CS            All male, 80% homeless                          161                                   0.6                                     0.0--3.4
                                 Kuo, 2006 [@pmed.1001663-Kuo1]                  2003                        Lahore                                              Harm reduction center                                CS                   All male                                 255                                   0.0                                       ---
                                                                                                             Quetta                                              Harm reduction center                                CS                   98% male                                 96                                    0.0                                       ---
                                Shah, 2004 [@pmed.1001663-Shah1]                 2003                       Larkana                                                                                                   CS                                                            175                                   9.7                                    5.8--15.1
                               Altaf, 2003[@pmed.1001663-Altaf2]                 2002                       Karachi                                              Harm reduction center                                CS            All male, 86% homeless                          153                                   0.0                                       ---
                                Hadi, 2005 [@pmed.1001663-Hadi1]                 2002              Rawalpindi, Swat, & Mardan                                            Mixed                                        CS                   65% male                                 500                                   3.4                                     2.0--5.4
                              Akhtar, 2004 [@pmed.1001663-Akhtar1]               2002                      Faisalabad                                       Voluntary drug treatment center                           CS                   All male                                 74                                    0.0                                       ---
                             Nai Zindagi, 1999 [@pmed.1001663-Nai2]              1999                        Lahore                                                    Community                                      CS                   All male                                 200                                   0.0                                       ---
                              Parviz, 2006 [@pmed.1001663-Parviz1]               1996                       Karachi                                   Voluntary drug treatment center & community                     CS                   All male                                 231                                   0.4                                     0.0--2.4
                                Baqi, 1998 [@pmed.1001663-Baqi1]                 1994                       Karachi                                  Voluntary and mandatory drug treatment center                    CS                   All male                                 120                                   0.0                                       ---
                               Iqbal, 1996 [@pmed.1001663-Iqbal1]             1987--2004                     Lahore                                                 Clinical setting                                  CS                                                            77                                    0.0                                       ---
                             Khanani, 2010 [@pmed.1001663-Khanani2]              ---                        Karachi                                                 Clinical setting                                  CS               Afghani refugees                             42                                    19.0                                   8.6--34.1
                            UrRehman, 2002 [@pmed.1001663-UrRehman1]             ---                        National                                                                                                                                                                400                                   0.0                                       ---
  **Syria**          Mental Health Directorate, 2008 [@pmed.1001663-Syria1]      2006                       Damascus                                                                                                 SBS                   96% male                                 204                                   0.5                                     0.1--2.7
  **Tunisia**            MOH, 2013 [@pmed.1001663-Tunisia1] (Round II)           2011                        Tunis                                                                                                   RDS                                                            506                   2.9[a](#nt105){ref-type="table-fn"}     1.3--4.4[a](#nt105){ref-type="table-fn"}
                                                                                                            Bizerte                                                                                                  RDS                                                            301                                   0.0                                       ---
                          MOH, 2010 [@pmed.1001663-Tunisia2] (Round I)           2009               Tunis, Bizerte, & Sousse                                                                                         RDS                   91% male                                 715                                   3.1                                     1.9--4.6

Population-adjusted estimate.

Self-report.

CS, convenience sampling; ID, infectious disease; MSCS, multi-stage cluster sampling; RCS, random cluster sampling; RDS, respondent driven sampling; SBS, snow ball sampling; SRS, simple random sampling; TLS, time location sampling; VCT, voluntary counseling and testing.

Three HIV incidence studies were identified. In Kabul, Afghanistan, HIV incidence among a sample of 479 PWID in 2008 was 2.2/100 person-years (pyr), despite 72% of study participants reporting use of harm reduction services [@pmed.1001663-Todd1]. Among 500 PWID in three cities in Pakistan, HIV incidence was 1.7/100 pyr in 2006 [@pmed.1001663-Hadi1]. A very high incidence rate (17.2/100 pyr) was reported in Tehran, Iran, in 2002 among 214 incarcerated PWID [@pmed.1001663-Jahani1].

Analysis of notified HIV cases indicated that in 2011, injecting drug use contributed 20% (80/409), 23% (50/216), 38% (6/16), 49% (52/107), and 60% (948/1,588) of all newly notified cases in this year in Egypt, Pakistan, Bahrain, Afghanistan, and Iran, respectively. A smaller contribution was reported in the remaining countries ([Table 4](#pmed-1001663-t004){ref-type="table"}).

10.1371/journal.pmed.1001663.t004

###### Contribution of injecting drug use as a mode of HIV transmission to the total HIV/AIDS cases by country as per various studies/reports and countries\' case notification reports [@pmed.1001663-World3],[@pmed.1001663-World4].

![](pmed.1001663.t004){#pmed-1001663-t004-4}

  Country         2011 Case Notification Report[a](#nt109){ref-type="table-fn"}   Cumulative Data since the Start of the Epidemic         
  -------------- --------------------------------------------------------------- ------------------------------------------------- ------ --------------
  Afghanistan                                  52                                                       107                         48.6   44.3% (2011)
  Bahrain                                       6                                                       16                          37.5   62.8% (2008)
  Egypt                                        80                                                       409                         19.6   1.6% (2008)
  Iran                                         948                                                     1,588                        59.7   69.4% (2011)
  Iraq                                         ---                                                      ---                         ---    0.0% (2009)
  Jordan                                        0                                                       17                          0.0    2.4% (2011)
  Kuwait                                        0                                                       25                          0.0    2.2% (2008)
  Lebanon                                       1                                                       51                          2.0    6.1% (2009)
  Morocco                                       9                                                       750                         1.2    2.7% (2011)
  Oman                                          5                                                       140                         3.6    4.3% (2011)
  OPT                                           0                                                        6                          0.0    2.8% (2011)
  Qatar                                         0                                                        1                          0.0        ---
  Pakistan                                     50                                                       216                         23.1   33.2% (2008)
  Saudi Arabia                                 46                                                       394                         11.7   6.4% (2009)
  Syria                                         0                                                       69                          0.0    2.4% (2009)
  Tunisia                                       3                                                       73                          4.1    24.4% (2009)
  UAE                                           1                                                       57                          1.8    3.6% (2011)
  Yemen                                         1                                                       236                         0.4    1.4% (2009)

Only the most recent available report was used.

Except for Bahrain, Egypt, and Iraq (2010 report) and Pakistan (2008 report).

*n*, number of positive cases that are PWID; *N*, total number of positive cases; Percent, percent of positive cases that are PWID out of the total number of positive cases; UAE, United Arab Emirates.

HIV Epidemic States {#s4e}
-------------------

The evidence was sufficient to characterize the HIV epidemic state in 13 countries, summarized in [Table 5](#pmed-1001663-t005){ref-type="table"}. Details on how the conclusions were reached are in [Text S3](#pmed.1001663.s010){ref-type="supplementary-material"}.

10.1371/journal.pmed.1001663.t005

###### Characterization of the state of the HIV epidemic among people who inject drugs in the Middle East and North Africa based on the HIV biological data and quality and scope of the evidence.
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  Country             Level of HIV Prevalence   Trend in HIV Prevalence   Geographical Distribution   Quality and Scope of Evidence
  ------------------ ------------------------- ------------------------- --------------------------- -------------------------------
  **Iran**                 Concentrated               Established                 National                     Conclusive
  **Pakistan**             Concentrated                Emerging                   National                     Conclusive
  **Afghanistan**          Concentrated                Emerging              At least localized                   Good
  **Egypt**                Concentrated                Emerging              At least localized                   Good
  **Morocco**              Concentrated                Emerging              At least localized                   Good
  **Libya**                Concentrated                 Unknown              At least localized                   Good
  **Bahrain**         At least outbreak-type              ---                        ---                         Limited
  **Oman**            At least outbreak-type              ---                        ---                          Poor
  **Jordan**                 Low-level                    ---                        ---                          Good
  **Lebanon**                Low-level                    ---                        ---                          Good
  **OPT**                    Low-level                    ---                        ---                          Good
  **Tunisia**                Low-level                    ---                        ---                          Good
  **Syria**                  Low-level                    ---                        ---                         Limited
  **Djibouti**                Unknown                     ---                        ---                          Poor
  **Iraq**                    Unknown                     ---                        ---                          Poor
  **Kuwait**                  Unknown                     ---                        ---                          Poor
  **Saudi Arabia**            Unknown                     ---                        ---                          Poor
  **Sudan**                   Unknown                     ---                        ---                          Poor
  **Yemen**                   Unknown                     ---                        ---                          Poor
  **Algeria**                 Unknown                     ---                        ---                       No evidence
  **Qatar**                   Unknown                     ---                        ---                       No evidence
  **Somalia**                 Unknown                     ---                        ---                       No evidence
  **UAE**                     Unknown                     ---                        ---                       No evidence

Countries are sorted by level of HIV prevalence, trend in HIV prevalence, geographical distribution, quality and scope of evidence, then alphabetical order.

UAE, United Arab Emirates.

### Concentrated HIV epidemics {#s4e1}

Concentrated HIV epidemics among PWID were observed in Iran, Pakistan, Afghanistan, Egypt, Morocco, and Libya ([Table 5](#pmed-1001663-t005){ref-type="table"}). Iran is the only country with conclusive evidence for an established concentrated epidemic at the national level. The first HIV outbreaks among PWID in Iran were reported around 1996. HIV prevalence then increased considerably in the early 2000s, reaching a peak by the mid-2000s ([Figure 3A](#pmed-1001663-g003){ref-type="fig"}). HIV prevalence in the 2006 and 2010 multi-city IBBSS was stable at 15% (*n* = 2,853 and *n* = 2,479, respectively) ([Figure 4C](#pmed-1001663-g004){ref-type="fig"}) [@pmed.1001663-Iran1],[@pmed.1001663-Iran2]. The evidence suggests that the HIV epidemic among PWID in Iran is now established at concentrated levels of about 15%.

![Trend of HIV prevalence among male people who inject drugs in (A) Iran and (B) Pakistan.\
This graph displays all available HIV prevalence measures for these two countries as extracted from eligible reports ([Table 3](#pmed-1001663-t003){ref-type="table"}) and various databases ([Table S4](#pmed.1001663.s004){ref-type="supplementary-material"}). Each dot represents one HIV prevalence measure for the specific year, and the bars around it define the 95% confidence interval. A pattern of established HIV epidemic is observed in Iran (A), while a trend of emerging HIV epidemic is observed in Pakistan (B).](pmed.1001663.g003){#pmed-1001663-g003}

![Trend of HIV prevalence among people who inject drugs, and when available men who have sex with men, in repeated rounds of bio-behavioral surveillance surveys.\
These graphs display the trend of HIV prevalence in repeated rounds of bio-behavioral surveillance surveys using state of the art sampling techniques for hard-to-reach populations including respondent driven sampling and time-location sampling. Country level and aggregate data of multiple cities/provinces are displayed. For consistency between countries and between different rounds within a given country, unadjusted sample estimates are displayed. Three main patterns of HIV epidemics among PWID are depicted. A pattern of emerging concentrated epidemics is observed in Pakistan (A) and Egypt (B); a pattern of established concentrated epidemic is observed in Iran (B); and a pattern of low-level HIV epidemic is observed in Tunisia (D). In Afghanistan (E), there is an emerging epidemic among PWID in apparently only part of the country; the effect of which was diluted in the second round with the inclusion of new cities with still very limited prevalence. The potential overlap of the HIV epidemics among PWID and MSM is depicted in Pakistan and Egypt. In Pakistan, an emerging HIV epidemic among transgender sex workers is observed, but lags the epidemic among PWID (A). In Egypt, the concentrated epidemic among MSM seems to have preceded the epidemic among PWID (B). In Tunisia, the potential link between the MSM and PWID epidemics is not clear because the studies were conducted after the epidemics had already risen.](pmed.1001663.g004){#pmed-1001663-g004}

Emerging concentrated epidemics were seen in Pakistan, Afghanistan, Egypt, and Morocco ([Table 5](#pmed-1001663-t005){ref-type="table"}). For example, in Pakistan, after almost two decades of very low HIV prevalence among PWID, a trend of increasing prevalence was observed after 2003 ([Figure 3B](#pmed-1001663-g003){ref-type="fig"}). This trend is national and ongoing, reaching over 40% in recent studies and with no evidence yet of stabilization ([Figure 3B](#pmed-1001663-g003){ref-type="fig"}). This trend also manifests itself in the multi-province IBBSS where HIV prevalence among PWID has steadily increased from 10.8% in 2005 (*n* = 2,431) [@pmed.1001663-Pakistan4], to 15.8% in 2006 (*n* = 4,039) [@pmed.1001663-Pakistan3], 20.8% in 2008 (*n* = 2,969) [@pmed.1001663-Pakistan2], and 25.2% in 2011 (*n* = 4,593) [@pmed.1001663-Pakistan1] ([Figure 4A](#pmed-1001663-g004){ref-type="fig"}). In view of the high HIV prevalence, the emerging HIV epidemic in Pakistan is considered advanced. Another example is Egypt where HIV prevalence was also very low for about two decades ([Tables 3](#pmed-1001663-t003){ref-type="table"} and [S4](#pmed.1001663.s004){ref-type="supplementary-material"}), including the first round of IBBSS in 2006 [@pmed.1001663-Family1],[@pmed.1001663-Soliman1], but increased to 6%--7% in both cities surveyed in the most recent IBBSS in 2010 (*n* = 284 and *n* = 274) ([Figure 4B](#pmed-1001663-g004){ref-type="fig"}) [@pmed.1001663-Family2]. Consistently, 19.6% of the 409 newly notified HIV cases in 2010 in Egypt were due to injecting drug use, compared with only 1.6% of the total notified cases up to 2008 ([Table 4](#pmed-1001663-t004){ref-type="table"}). In Afghanistan ([Figure 4E](#pmed-1001663-g004){ref-type="fig"}) and Morocco, the HIV epidemic among PWID appears to be emerging in at least parts of the country, with notably high HIV prevalence in some settings, but still low HIV prevalence in others ([Table 3](#pmed-1001663-t003){ref-type="table"}).

The HIV epidemic in Libya is also concentrated, but the trend is unclear. Libya has the highest reported prevalence of HIV among PWID in MENA (87.2%, 95% CI 83.1%--90.6% in the IBBSS in Tripoli [@pmed.1001663-Mirzoyan1]). Earlier data, although of unclear quality, also indicate prevalence of up to 59% in 2001 among PWID in Tripoli ([Table S4](#pmed.1001663.s004){ref-type="supplementary-material"}). This indicates a concentrated HIV epidemic among PWID in at least part of Libya. Although the epidemic in Tripoli is most likely to be established, the level of evidence overall is insufficient to characterize whether the national epidemic is emerging, with few outbreaks in the past, or is established with endemic HIV transmission among PWID.

### "At least outbreak-type" HIV epidemics {#s4e2}

In Bahrain and Oman, data show that there are, or have been, at least some pockets of HIV infection among PWID, with reported prevalence up to 21.1% (Bahrain, *n* = 242) [@pmed.1001663-AlHaddad1] and 27% (Oman, *n* = 33) [@pmed.1001663-Oman1]. However, most available data are from studies with unknown methodology or high ROB; therefore, the quality of evidence is insufficient to indicate whether there is a concentrated epidemic in these two countries, even if localized.

### Low-level HIV epidemics {#s4e3}

The HIV epidemic among PWID is low-level in Jordan, Lebanon, Tunisia, OPT, and Syria ([Table 5](#pmed-1001663-t005){ref-type="table"}). In these countries (except Syria), at least one round of IBBSS has been conducted, in addition to other data; all indicate limited HIV spread among PWID ([Figure 4D](#pmed-1001663-g004){ref-type="fig"}; [Tables 3](#pmed-1001663-t003){ref-type="table"} and [S4](#pmed.1001663.s004){ref-type="supplementary-material"}). The contribution of injecting drug use to the total notified cases also remains minimal in these countries, further confirming a low-level epidemic ([Table 4](#pmed-1001663-t004){ref-type="table"}).

Injecting Risk Behavior {#s4f}
-----------------------

[Table S5](#pmed.1001663.s005){ref-type="supplementary-material"} summarizes injecting risk behavior measures among PWID in MENA. The key risk behavior that exposes PWID to HIV infection is the use of non-sterile injecting equipment. Available data indicate that the lifetime prevalence of sharing needles/syringes among PWID in MENA was as high as 71% [@pmed.1001663-Jordan1], 79% [@pmed.1001663-Nai1], 85% [@pmed.1001663-Mirzoyan1], 95% [@pmed.1001663-Kazerooni1], and 97% [@pmed.1001663-Oman1] in Jordan, Pakistan, Libya, Iran, and Oman, respectively. The median prevalence of sharing in the last injection was 23% (IQR: 18%--28%). In Pakistan, most injecting occurs in groups and in public places, and reported use of "street doctors" or professional injectors was common, which is associated with high reuse of injecting equipment ([Table S5](#pmed.1001663.s005){ref-type="supplementary-material"}) [@pmed.1001663-Pakistan2].

In MENA, PWID inject drugs at median of 2.2 injections per day, with reported rates of 3.3 [@pmed.1001663-Asadi1] and 5.7 [@pmed.1001663-Todd2] injections per day among some PWID in Iran and Afghanistan, respectively. The median age at first injection was 26 years (IQR: 24--28 years), and the median duration of injecting drugs was 4.6 years (IQR: 3.8--6.1 years) ([Table S5](#pmed.1001663.s005){ref-type="supplementary-material"}).

Sexual Risk Behavior {#s4g}
--------------------

The majority of PWID in MENA are sexually active ([Table S6](#pmed.1001663.s006){ref-type="supplementary-material"}). On average, 52% have been ever married (IQR: 35%--56%), 43%--89% report having sex with a regular female partner, 29%--60% reported multiple sexual partnerships, and 18%--42% report sex with non-regular female partners in the last year ([Table S6](#pmed.1001663.s006){ref-type="supplementary-material"}). Reported levels of condom use varied but generally were on the low to intermediate range. Overall, 36% of PWID reported ever using condoms (IQR: 20%--54%) with the lowest prevalence in Afghanistan and Pakistan (10%--38% [@pmed.1001663-Kuo1]--[@pmed.1001663-Todd3]), and the highest in Lebanon (88% [@pmed.1001663-Aaraj1]). Condom use during last sex was reported by 4%--38% of PWID, reaching 66% only in Libya [@pmed.1001663-Mirzoyan1]. Only 12%--25% of PWID reported consistent condom use in the last year ([Table S6](#pmed.1001663.s006){ref-type="supplementary-material"}).

Mixing with Other High-Risk Populations {#s4h}
---------------------------------------

Risk behaviors of PWID in MENA overlap considerably with other high-risk populations, namely MSM and female sex workers. A median of 18% of male PWID in MENA reported ever having sex with men (IQR: 11%--27%), and a median of 7% did so in the last year (IQR: 2%--10%) ([Table S6](#pmed.1001663.s006){ref-type="supplementary-material"}). The highest rates of same-sex sex have been reported in Pakistan. Reported condom use during anal sex was overall very low ([Table S6](#pmed.1001663.s006){ref-type="supplementary-material"}).

PWID in MENA engage in sex work, either through buying or selling sex. A median of 45% reported ever having sex with a sex worker (IQR: 31%--64%), and a median of 23% did so in the last year (IQR: 15%--30%), with generally low levels of condom use ([Table S6](#pmed.1001663.s006){ref-type="supplementary-material"}). Selling sex in the past year was reported by 5%--29% of PWID in Egypt, Iran, Morocco, OPT, and Pakistan ([Table S6](#pmed.1001663.s006){ref-type="supplementary-material"}).

Proxy Biological Markers of Risk Behavior {#s4i}
-----------------------------------------

There was substantial between-and within-country variation in HCV prevalence among PWID, with a median of 44% (IQR: 31%--64%) ([Table 6](#pmed-1001663-t006){ref-type="table"}). Very high HCV prevalence was reported such as in Afghanistan (70%, *n* = 185, Herat), Egypt (63%, *n* = 100, Alexandria), Iran (over 80%, *n* = 386 prisoners, Tehran), Libya (94%, *n* = 328, Tripoli), Pakistan (94%, *n* = 161, Karachi), and Saudi Arabia (75%, *n* = 1,909, Jeddah) ([Table 6](#pmed-1001663-t006){ref-type="table"}). These figures are consistent with the reported high levels of sharing of injection equipment, such as in Iran, Pakistan, and Libya ([Table S5](#pmed.1001663.s005){ref-type="supplementary-material"}).

10.1371/journal.pmed.1001663.t006

###### Prevalence of hepatitis C virus among people who inject drugs in the Middle East and North Africa.
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  Country                        HCV Prevalence                 Year      Sample Size   Population Characteristics                             City                                               Source                    
  ------------------ -------------------------------------- ------------ ------------- ---------------------------- ---------------------------------------------------------- -------------------------------------------- ---------------------------------
  **Afghanistan**                     70.0                   63.1--76.8      2012                  185                                  Predominantly male                                        Herat                       [@pmed.1001663-Afghanistan2]
                                      57.9                   49.8--65.6      2009                  159                                  Predominantly male                                        Herat                       [@pmed.1001663-Afghanistan1]
                                      49.1                   43.7--54.6   2006--2008               340                                  Predominantly male                                        Herat                          [@pmed.1001663-Nasir1]
                                      37.1                   31.5--42.9      2009                  286                                  Predominantly male                                        Kabul                       [@pmed.1001663-Afghanistan1]
                                      36.6                   32.1--41.1   2006--2008               463                                  Predominantly male                                        Kabul                          [@pmed.1001663-Nasir1]
                                      36.1                   31.7--40.5   2007--2009               483                                  Predominantly male                                        Kabul                           [@pmed.1001663-Todd2]
                                      27.6                   23.1--32.5      2012                  369                                  Predominantly male                                        Kabul                       [@pmed.1001663-Afghanistan2]
                                      25.5                   17.4--35.1      2009                  102                                  Predominantly male                                    Mazar-i-Sharif                  [@pmed.1001663-Afghanistan1]
                                      25.0                   17.3--33.6      2012                  117                                  Predominantly male                                       Charikar                     [@pmed.1001663-Afghanistan2]
                                      24.1                   18.1--30.8   2006--2008               187                                  Predominantly male                                    Mazar-i-Sharif                     [@pmed.1001663-Nasir1]
                                      18.8                   14.3--24.3      2012                  254                                  Predominantly male                                    Mazar-i-Sharif                  [@pmed.1001663-Afghanistan2]
                                      12.5                   6.6--20.8    2006--2008                96                                  Predominantly male                                      Jalalabad                        [@pmed.1001663-Nasir1]
                                      9.5                    5.9--13.8       2012                  236                                  Predominantly male                                      Jalalabad                     [@pmed.1001663-Afghanistan2]
  **Egypt**                           63.0                   52.8--72.4      1994                  100                                                                                          Alexandria                       [@pmed.1001663-Saleh1]
  **Iran**                            95.4                   77.2--99.9   2002--2003                22                                      Prisoners                                             Gorgan                         [@pmed.1001663-Behnaz1]
                                      88.9                   80.0--94.8      2003                   81                             Predominantly male prisoners                                  Guilian                     [@pmed.1001663-MohtashamAmiri1]
                                      80.5                   76.3--84.4   2001--2002               386                             Predominantly male prisoners                                   Tehran                       [@pmed.1001663-MirNasseri1]
                                      80.1                   76.2--83.7      1998                  464                                                                                            Shiraz                     [@pmed.1001663-Mirahmadizadeh1]
                                      80.0                   76.0--83.5      2006                  454                                  Predominantly male                                        Tehran                      [@pmed.1001663-Kheirandish2]
                                      76.8                   72.4--80.9      2003                  401                             Predominantly male prisoners                 Isfahan, Chaharmahal Bakhtiary, & Lorestan     [@pmed.1001663-Pourahmad1]
                                      67.4                   49.5--82.6       ---                   34                                                                                            Tehran                         [@pmed.1001663-Amini1]
                                      65.9                   59.8--71.7      2008                  258                                  Predominantly male                                        Tehran                      [@pmed.1001663-Eskandarieh1]
                                      64.8                   58.4--70.6      2002                  249                                      Prisoners                                           Hormozgan                      [@pmed.1001663-Davoodian1]
                                      63.3                   56.2--70.0   2005--2007               199                                                                                           Hamadan                        [@pmed.1001663-Keramat1]
                                      59.4                   47.4--68.7      2008                  117                                  Predominantly male                                     Foulad-Shahr                      [@pmed.1001663-Zamani4]
                                      59.4                   49.2--69.1   2001--2002               101                                      Prisoners                                            Mashhad                         [@pmed.1001663-Rahbar1]
                                      52.9                   35.1--70.2      2007                   34                             Predominantly male, homeless                                   Tehran                        [@pmed.1001663-Vahdani1]
                                      52.1                   43.6--60.6   2001--2006               142                                  Predominantly male                                        Ahfaz                          [@pmed.1001663-Alavi3]
                                      52.0                   44.9--59.0      2004                  202                                  Predominantly male                                        Tehran                         [@pmed.1001663-Zamani6]
                                      50.0                   11.8--88.2   2008--2009                6                                 Incarcerated juveniles                                     Isfahan                       [@pmed.1001663-Nokhodian1]
                                      50.0                   21.1--78.9      2006                   12                                                                                          Kermanshah                       [@pmed.1001663-Sayad1]
                                      50.0                   41.4--58.6       ---                  138                                  Predominantly male                                        Shiraz                        [@pmed.1001663-Alavian1]
                                      47.1                   42.8--51.4   2008--2009               531                                  Predominantly male                                       Isfahan                       [@pmed.1001663-Nokhodian2]
                                      45.3                   40.3--50.3      1995                  402                             Predominantly male prisoners                                   Tehran                          [@pmed.1001663-Zali1]
                                      44.4                   27.9--61.9   2006--2007                36                                       Females                                              Tehran                     [@pmed.1001663-RahimiMovaghar1]
                                      43.4                   40.8--45.9       ---                 1,485                                 Predominantly male                                     Foulad-Shahr                      [@pmed.1001663-Ataei1]
                                      43.4                   40.2--46.6       ---                  936                                  Predominantly male                                       National                    [@pmed.1001663-Mirahmadizadeh2]
                                      42.4                      ---       2009--2010               ---                                                                                   Kohgiloyeh & Boyerahmad                [@pmed.1001663-Sarkari1]
                                      42.0                   38.8--45.2       ---                  951                                      Prisoners                                          Foulad-Shahr                    [@pmed.1001663-Kaffashian1]
                                      41.6                   38.4--44.8   2008--2009               943                             Predominantly male prisoners                                  Isfahan                        [@pmed.1001663-Kassaian1]
                                      40.3                   34.0--46.9   2012--2013               233                                  Predominantly male                                        Shiraz                        [@pmed.1001663-Honarvar1]
                                      38.6                   32.1--45.2      2010                  226                                  Predominantly male                              Tehran, Shiraz, & mashhad               [@pmed.1001663-Alipour1]
                                      37.5                   20.4--54.9   2007--2009                33                                                                                             Sari                        [@pmed.1001663-Ghasemian1]
                                      36.6                   21.6--52.0      2010                   42                           Female sexual partners of PWIDs                        Tehran, Shiraz, & mashhad               [@pmed.1001663-Alipour1]
                                      36.5                   28.2--45.2   2001--2002               132                                  Predominantly male                                        Tehran                       [@pmed.1001663-MirNasseri1]
                                      36.0                   24.6--48.1      2007                   70                                                                                            Tehran                       [@pmed.1001663-Aminzadeh1]
                                      34.1                   30.9--37.4   2006--2007               859                                  Predominantly male                                        Tehran                     [@pmed.1001663-RahimiMovaghar1]
                                      34.0                   31.8--36.3   2008--2009              1,747                                 Predominantly male                                       Isfahan                         [@pmed.1001663-Nobari1]
                                      31.5                   24.2--39.7      2002                  149                             Predominantly male prisoners                                  Hamadan                        [@pmed.1001663-Alizadeh1]
                                      30.9                   26.0--36.2   2002--2006               333               Predominantly males, hospitalized for infectious disease                     Ahfaz                          [@pmed.1001663-Alavi2]
                                      22.8                   9.6--41.1    2000--2005                31                         Hospitalized for infectious disease                               Zahedan                      [@pmed.1001663-SharifiMood1]
                                      16.1                   5.5--33.7       2003                   31                                                                                          Rafsanjan                    [@pmed.1001663-Khodadadizadeh1]
                                      13.0                   2.8--33.6    2001--2006                23                     Females, hospitalized for infectious disease                           Kashan                         [@pmed.1001663-Sharif1]
                                      12.9                   2.8--33.6       2006                   23                                                                                      Tehran & Hormozgan                   [@pmed.1001663-Merat1]
                                      11.9                   7.5--17.6    2001--2006               177               Predominantly males, hospitalized for infectious disease                     Kashan                         [@pmed.1001663-Sharif1]
                                      11.3                   6.5--17.9       2004                  133                                  Predominantly male                                     Shahr-e-Kord                      [@pmed.1001663-Imani1]
                      26.8[a](#nt114){ref-type="table-fn"}   20.9--33.3      2011                  209                                  Predominantly male                                        Tehran                       [@pmed.1001663-Mehrjerdi1]
  **Lebanon**                         51.0                     33--74     2007--2008                43                                                                                            Beirut                        [@pmed.1001663-Mahfoud1]
                                      5.0                    0.6--16.9    2000--2002                40                                      25% female                                            Beirut                         [@pmed.1001663-Ramia1]
  **Libya**                           94.2                   90.8--96.7      2010                  328                                  Predominantly male                                       Tripoli                        [@pmed.1001663-Mirzoyan1]
  **Morocco**                         79.2                   72.1--85.7   2011--2012               274                                  Predominantly male                                        Nador                         [@pmed.1001663-Morocco2]
                                      45.6                   35.5--56.6   2010--2011               261                                  Predominantly male                                        Tanger                        [@pmed.1001663-Morocco2]
  **Oman**            36.0[a](#nt114){ref-type="table-fn"}   12.8--64.9       ---                   14                                  Predominantly male                                        Muscat                          [@pmed.1001663-Oman1]
                      11.0[a](#nt114){ref-type="table-fn"}   0.3--48.2        ---                   9                              Predominantly male prisoners                                   Muscat                          [@pmed.1001663-Oman1]
                      53.0[a](#nt114){ref-type="table-fn"}   40.0--66.3       ---                   60                                  Predominantly male                                        Muscat                          [@pmed.1001663-Oman1]
  **OPT**                             40.3                   29.2--52.2      2010                  192                                  Predominantly male                                    East Jerusalem                   [@pmed.1001663-Stulhofer1]
  **Pakistan**                        94.3                   89.7--97.4      2003                  161                                                                                           Karachi                         [@pmed.1001663-Altaf1]
                                      92.9                   89.1--95.8      2003                  255                                  Predominantly male                                        Lahore                          [@pmed.1001663-Kuo1]
                                      91.8                   88.6--94.4      2004                  380                                  Predominantly male                                        Lahore                         [@pmed.1001663-Rehan1]
                                      89.0                   83.8--93.0      1999                  200                                  Predominantly male                                        Lahore                          [@pmed.1001663-Nai2]
                                      89.0                   85.5--91.9       ---                  400                                                                                           National                       [@pmed.1001663-UrRehman1]
                                      87.0                   83.3--90.1      2004                  399                                  Predominantly male                                       Karachi                         [@pmed.1001663-Rehan1]
                                      86.9                   80.5--91.8      2002                  153                                       Homeless                                            Karachi                         [@pmed.1001663-Altaf2]
                                      76.0                      ---          2005                  ---                                  Predominantly male                                        Lahore                         [@pmed.1001663-Rahman1]
                                      75.0                   65.1--83.3      2003                   96                                  Predominantly male                                        Quetta                          [@pmed.1001663-Kuo1]
                                      62.5                   24.5--91.5   2007--2009                8                                Remote rural population                                       Kech                          [@pmed.1001663-Ahmed1]
                                      60.0                   45.2--73.6      2004                   50                                                                                            Quetta                        [@pmed.1001663-Achakzai1]
                                      46.4                   34.5--57.9       ---                   76                             Predominantly male prisoners                                   Kabul                           [@pmed.1001663-Butt1]
                                      45.2                   29.8--61.3       ---                   42                                   Afghani refugees                                        Karachi                        [@pmed.1001663-Khanani2]
                                      44.7                   39.0--50.5      2003                  300                                  Predominantly male                                        Quetta                         [@pmed.1001663-Abbasi2]
                                      42.0                   37.6--46.5      2002                  500                                      35% female                                        mix of cities                       [@pmed.1001663-Hadi1]
                                      31.5                   25.1--38.4       ---                  200                                  Predominantly male                                  Khyber pakhtunkhwa                  [@pmed.1001663-UrRehman2]
                                      17.3                   13.1--22.0      2007                  302                                  Predominantly male                                      Rawalpindi                       [@pmed.1001663-Platt1]
                                      14.3                   5.4--28.5        ---                   42                                                                                      Khyber pakhtunkhwa                    [@pmed.1001663-Ali1]
                                      8.0                    3.4--14.9       2007                  102                                  Predominantly male                                       Abotabad                        [@pmed.1001663-Platt1]
  **Saudi Arabia**                    74.6                   72.6--76.5   1995--1996               1909                                 Predominantly male                                        Jeddah                          [@pmed.1001663-Njoh1]
                                      69.0                   64.7--72.9   1995--1996               505                                                                                                                           [@pmed.1001663-Iqbal2]
                                      38.1                   32.9--43.4       ---                  344                                                                                                                         [@pmed.1001663-Alzahrani1]
  **Syria**                           60.5                   43.4--76.0      2006                   38                                  Predominantly male                                       Damascus                        [@pmed.1001663-Othman1]
                      21.0[a](#nt114){ref-type="table-fn"}   11.4--33.9      2006                   57                                  Predominantly male                                       Damascus                        [@pmed.1001663-Syria1]
  **Tunisia**                         35.8                   29.1--42.5      2011                  506                                  Predominantly male                                        Tunis                         [@pmed.1001663-Tunisia1]
                                      29.1                   25.8--32.6      2009                  701                                  Predominantly male                               Tunis, Bizerte, & Sousse               [@pmed.1001663-Tunisia2]
                                      2.4                     0.6--4.1       2011                  301                                  Predominantly male                                       Bizerte                        [@pmed.1001663-Tunisia1]

The table is sorted by country then by descending order of HCV prevalence.

Self report.

Available data on the prevalence of syphilis among PWID in Egypt, Iran, Afghanistan, and Pakistan indicate relatively high prevalence up to 3%, 8%, 17%, and 18%, respectively ([Table S6](#pmed.1001663.s006){ref-type="supplementary-material"}). Considerable herpes simplex virus type 2 prevalence has been reported among PWID in Afghanistan (4%--21%) and Pakistan (6%--19%) ([Table S6](#pmed.1001663.s006){ref-type="supplementary-material"}). Data on the prevalence of gonorrhoea (0%--1.8%) and chlamydia (0%--0.7%) were available only in Pakistan ([Table S6](#pmed.1001663.s006){ref-type="supplementary-material"}).

Knowledge of HIV/AIDS {#s4j}
---------------------

Levels of basic HIV/AIDS knowledge among PWID in MENA were high overall, with a median of 93% having ever heard of HIV/AIDS (IQR: 72%--99%). Still, there was much variation in the proportion of PWID who correctly identified reuse of non-sterile needles/syringes and unprotected sex as modes of HIV transmission ([Table S7](#pmed.1001663.s007){ref-type="supplementary-material"}). Only a median of 45% (IQR: 30%--63%) of PWID perceived themselves at risk of HIV/AIDS ([Table S7](#pmed.1001663.s007){ref-type="supplementary-material"}). With a few exceptions of high levels of HIV testing such as in Lebanon and Oman, the median prevalence of lifetime testing among PWID ranged between 8% (Egypt) and 45% (Iran) ([Table S7](#pmed.1001663.s007){ref-type="supplementary-material"}).

Discussion {#s5}
==========

Injecting Drug Use in MENA {#s5a}
--------------------------

We estimate that there are 626,000 PWID in the MENA region. Overall, the mean prevalence of injecting drug use (0.24%) is comparable with global figures which range from 0.06% in South Asia to 1.50% in Eastern Europe [@pmed.1001663-Mathers1]. Prevalence of injecting drug use in MENA varied between countries and was higher in the eastern part of the region. Injecting drug use appears to be heavily concentrated among men; but female PWID are one of the hardest-to-reach populations in MENA, thereby limiting our knowledge of this vulnerable group. From limited available data, it appears that injecting drug use among females has a strong association with sex work and having a PWID sexual partner [@pmed.1001663-Burns1],[@pmed.1001663-Alipour1].

Emerging HIV Epidemics and HIV Epidemic Potential among PWID {#s5b}
------------------------------------------------------------

After synthesizing a large body of data, we documented HIV epidemics among PWID in one-third of MENA countries. The HIV epidemic is in a concentrated state in about half the countries with available data. Iran is the only country with an established concentrated epidemic, while the most common pattern is that of emerging concentrated epidemics. Most observed epidemics in the region are recent, occurring only in the last decade; around the same time that HIV epidemics among MSM appear to have emerged (2003) [@pmed.1001663-Mumtaz2]. Of note, our classification of epidemic states did not depend only on the size of the epidemic, but also on the trend of HIV prevalence and other biological data. For example in Pakistan, despite high HIV prevalence, the epidemic was classified as emerging since HIV prevalence continues in an increasing trend. HIV prevalence among PWID in MENA countries with concentrated epidemics is overall in the range of 10%--15%, which is in the intermediate range compared to global figures [@pmed.1001663-Mathers1]. However, there are settings with very high prevalence, most notably in Tripoli, Libya, which appears to have one of the highest HIV prevalence reported globally (87.1%) [@pmed.1001663-Mathers1],[@pmed.1001663-Mirzoyan1].

In about 20% of MENA countries, the HIV epidemic among PWID was low level, with HIV prevalence consistently low for many years including the most recent IBBSS. In some countries, such as Jordan, Lebanon, and OPT, no HIV infections were found in the IBBSS. The available evidence in countries at low level is restricted to a few cities, and there could be hidden sub-epidemics in other sites. Nevertheless, the low prevalence could be reflective of the intrinsic HIV transmission dynamics, levels of risk behavior, and/or injecting network structure. HIV may not have been introduced to the PWID community, may have been recently introduced, or may have been spreading slowly and inefficiently for some time. The latter may reflect injecting networks with infrequent and few repeated transmission contacts among PWID to sustain HIV dynamics. In Lebanon and Syria for example, it appears that PWID form closed small networks with injecting occurring in private homes and among friends, and not in large groups or at shooting galleries [@pmed.1001663-Syria1],[@pmed.1001663-Mishwar1]. The low prevalence could also be a consequence of stochastic effects where the small number of individuals who introduced HIV to the PWID population happened by chance not to have links that could sustain transmission chains.

Whilst it is conceivable that HIV prevalence may not grow in countries currently at low level, there are settings where HIV prevalence increased considerably in a short period of time. For example in Karachi, Pakistan, after several years of near zero prevalence [@pmed.1001663-Altaf1],[@pmed.1001663-Altaf2],[@pmed.1001663-Baqi1],[@pmed.1001663-Parviz1], HIV prevalence in 2004 increased to 23% in less than 6 months [@pmed.1001663-Bokhari1], and reached 42% in 2011 [@pmed.1001663-Pakistan1]. This pattern is not surprising given the reported risky practices and high HCV prevalence. When HIV prevalence was still very low in Karachi, HCV prevalence was over 85% [@pmed.1001663-Altaf1],[@pmed.1001663-Altaf2], indicating substantial use of non-sterile injecting equipment and suggesting connectivity of injecting networks. In Iran, the substantial HCV prevalence (up to 80%) was predictive of the explosive HIV epidemic that occurred subsequently. In both Iran and Pakistan, injecting networks often seem to be well connected and we found reports of injecting and sharing occurring among persons who are not necessarily socially related, e.g. in shooting galleries [@pmed.1001663-Razzaghi1],[@pmed.1001663-Emmanuel2]. Data on HCV prevalence among PWID in MENA countries with low-level HIV epidemics are limited. However, HCV prevalence of 40%--61% among some PWID groups such as in Lebanon, OPT, and Syria suggest moderate HIV epidemic potential once the virus is introduced to the PWID community.

Bridging of the HIV Epidemic to Other Population Groups {#s5c}
-------------------------------------------------------

We found considerable overlap of risk behavior between PWID and other high-risk groups in MENA; this could play a role in emerging HIV epidemics, as it creates opportunities for an infection circulating in one population to be bridged to another one. In Pakistan, the rapidly growing HIV epidemic among PWID was followed closely by an emerging epidemic among transgender sex workers ([Figure 4A](#pmed-1001663-g004){ref-type="fig"}). Phylogenetic analyses found clustering of subtypes between the two populations, suggesting that the infection might have bridged from PWID to the transgender population [@pmed.1001663-Khanani1]. A similar pattern, but in the opposite direction, may have occurred in Egypt where an emerging epidemic among MSM [@pmed.1001663-Mumtaz2] preceded the nascent epidemic among PWID ([Figure 4B](#pmed-1001663-g004){ref-type="fig"}). While supported by behavioral data [@pmed.1001663-Family1],[@pmed.1001663-Family2], this needs to be confirmed by phylogenetic analyses.

Our analysis, focused on the HIV disease burden among PWID, still masks the role of these epidemics in driving the onward transmission of HIV to the sexual partners of PWID and further in the population. The majority of PWID are sexually active and about half are married. They often engage in risky sexual behavior as confirmed by the prevalence of STIs. This puts sexual partners of PWID at risk of HIV. A substantial number of infections in MENA have been documented in women who acquired HIV from their PWID husbands; and in some countries, the majority of HIV infections among women were acquired from a PWID sexual partner [@pmed.1001663-Alipour1],[@pmed.1001663-Ramezani1]--[@pmed.1001663-Nai3]. This highlights the vulnerability of sexual partners of PWID, who are often female spouses. An illustration of the role of the HIV epidemics among PWID in driving the onward transmission of HIV emerges from recent mode of transmission (MoT) modeling studies in the region [@pmed.1001663-Mumtaz4]--[@pmed.1001663-Gouws1]. For example, in Iran, PWID directly contributed 56% of the total HIV Incidence; and indirectly, only through infections to their current sexual partners, an additional 12% of the total incidence [@pmed.1001663-Gouws1]. More onward HIV transmissions would arise if the sexual partners of PWID transmitted the infection to their other sexual partners.

Study Limitations {#s5d}
-----------------

One limitation of our study is that the quantity and quality of data varied by countries. There were virtually no HIV data in four countries, and the data quality in six others was insufficient to assess the status of the epidemic. Longitudinal repeated IBBSS data were available in only five countries. Six countries have recently conducted their first round of IBBSS; and in most of these, subsequent rounds are either planned or being implemented. The quality of data was "good" or "conclusive" in ten out of the 23 countries.

While most of the data were from cross sectional surveys, there was a substantial improvement in the quality of data over time. Many studies were conducted with state of the art research methodologies in HIV research. These consist of IBBSS studies using innovative sampling methodologies for hard-to-reach populations such as respondent-driven sampling and time-location sampling. Most of these studies benefited from large sample sizes and some from broad geographical coverage at the national level.

Of note that in several countries there were no recent national estimates of the number and proportion of PWID. The only national data available for these countries were extracted from earlier global reviews of injecting drug use [@pmed.1001663-Aceijas2],[@pmed.1001663-Mathers1]. The reviews were based mainly on estimates by the Reference Group to the UN on HIV and Injecting Drug Use, which systematically collects and analyses global data on injecting drug use and HIV [@pmed.1001663-IDU1]. The Reference Group is considered the main reference for PWID estimates globally, providing the estimates to the United Nations Office on Drugs and Crime (UNODC), WHO, and UNAIDS secretariats. We complemented the Reference Group data with PWID national risk-group size estimation studies that were conducted in the last few years in five countries namely Afghanistan, Iran, Pakistan, Saudi Arabia, and Tunisia. Since we partly relied on secondary sources of data and since the data that we used came from studies using different methodologies, our pooled estimates of the number and prevalence of PWID in MENA should be considered as approximate figures.

In assessing the status of the epidemic at the country-level, we did not limit our analysis to one line of evidence, but synthesized and corroborated findings from different data sources and types such as HIV prevalence and incidence, notified HIV cases, injecting and sexual risk behavior, and other related and contextual data. Thus we could make a comprehensive assessment of the epidemic status and address potential limitations in any one line of evidence [@pmed.1001663-Rutherford1]. We did a rigorous appraisal of the scope and quality of the evidence within each country by assessing the amount and geographical coverage of available data, as well as the ROB and precision of individual point estimates. A qualifier for the scope and quality of the evidence at the country level was integrated with each HIV epidemic state assigned. Our search criteria were expansive, covering different literature sources. Before the present submitted work, the status of the epidemic across MENA country was poorly understood. On the basis of our integrated data synthesis and using rigorous methodology and data quality assessment, we were able to concretely qualify the epidemic status in 13 countries (over half of MENA countries), and to document the overall trend of emerging epidemics. The lack of evidence in several MENA countries does not preclude the possibility of hidden epidemics among PWID in these settings.

HIV Response among PWID in MENA {#s5e}
-------------------------------

Not only does the region overall lag behind in responding to the emerging HIV epidemics among PWID; in occasions misguided policy has contributed to these epidemics. Most notably in Libya, the large HIV epidemic among PWID appears to have been exacerbated by restrictions imposed on the sale of needles and syringes at pharmacies in the late 1990s [@pmed.1001663-AbuRaddad1],[@pmed.1001663-Tawilah1]. Overall, harm reduction programs still remain limited in MENA, and there is a need to integrate such programs within the socio-cultural framework of the region [@pmed.1001663-Hasnain1]. Several countries though have made significant strides in initiating such programs in recent years [@pmed.1001663-AbuRaddad1],[@pmed.1001663-Harm1]. Needle/syringe exchange programs are currently implemented in nine countries, and opioid substitution therapy in five [@pmed.1001663-Harm1]. Iran remains the leader in the provision of harm reduction services to PWID with the highest coverage of needle/syringe exchange programs in the region [@pmed.1001663-AbuRaddad2],[@pmed.1001663-Harm1]. It appears also to be the only country in MENA to provide such services in prisons [@pmed.1001663-Harm1],[@pmed.1001663-Asfhar1] and to provide female-operated harm reduction services targeted at female drug users [@pmed.1001663-Harm1].

Iran has also initiated triangular clinics that integrate services for treatment and prevention of injecting drug use, HIV/AIDS, and other STIs; and these clinics have received international recognition as best practice [@pmed.1001663-WHO1]--[@pmed.1001663-Nassirimanesh1]. Among other interventions implemented in Iran are drop-in centers, integration of substance use treatment and HIV prevention into the rural primary health care system, and community education centers [@pmed.1001663-Mojtahedzadeh1],[@pmed.1001663-Iran3]--[@pmed.1001663-Zamani2]. These efforts appear to have been successful in reducing sharing of injecting equipment [@pmed.1001663-Vazirian1]--[@pmed.1001663-Bolhari1], though the coverage of harm reduction continues to be lower than adequate [@pmed.1001663-Todd4].

Other countries in the region have also made progress in revising their policies, adopting harm reduction programs, and integrating such programs in their national strategic plans such as Afghanistan, Egypt, Lebanon, Morocco, Pakistan, and Tunisia [@pmed.1001663-AbuRaddad1],[@pmed.1001663-AbuRaddad3]. Access to antiretroviral therapy (ART) has also expanded in MENA in recent years, and treatment outcomes reported by country ART programs are comparable to globally reported outcomes [@pmed.1001663-WHOEMRO2],[@pmed.1001663-WHOEMRO3]. Good adherence to ART has been also observed, such as in Morocco [@pmed.1001663-Benjaber1], though some non-adherence and treatment interruptions, among other obstacles, have been also reported in several countries [@pmed.1001663-Benjaber1]--[@pmed.1001663-UNAIDS3].

Non-governmental organizations (NGOs) have been instrumental to the success in harm reduction in MENA. It can be noted that in countries where NGOs are strong, HIV response has been also strong [@pmed.1001663-AbuRaddad1],[@pmed.1001663-AbuRaddad3]. The Iranian NGO Persepolis, for example, played an important role in the transformation to effective policies in Iran [@pmed.1001663-Razzaghi2]. Building on the growing role of NGOs, a regional civil society network was established in 2007 covering 20 countries in MENA; the Middle East and North Africa Harm Reduction Association (MENAHRA) [@pmed.1001663-Middle1]. MENAHRA has the objective of building the capacity of civil society organizations in harm reduction efforts through training, sharing of information, networking and providing direct support to NGOs to initiate or scale-up harm reduction services. The network is a collaborative initiative by regional and international organizations with funding from international donors, and has been influential in promoting harm reduction.

Despite the recent progress in harm reduction, HIV prevention efforts among PWID in MENA remain impeded by generic and routine planning, competing priorities, limited human capital, and lack of monitoring and evaluation [@pmed.1001663-Kilmarx1]. National policies remain inadequate and not sufficiently reflecting evidence-informed approaches [@pmed.1001663-Kilmarx1]. The scope and coverage of prevention services remain patchy across and within countries [@pmed.1001663-AbuRaddad1],[@pmed.1001663-Harm1],[@pmed.1001663-AbuRaddad3]. An indicator of the low effective coverage is that only a minority of PWID report ever being tested, and a smaller proportion report being tested within the last year [@pmed.1001663-AbuRaddad1]. In Morocco and Pakistan, two countries with a strong HIV response, only 32.5% [@pmed.1001663-Morocco2], 47.8% [@pmed.1001663-Morocco2], 6.1% [@pmed.1001663-Pakistan3], and 20.7% [@pmed.1001663-Pakistan2] of PWID in different surveys reported ever being tested. Even where services are available, PWID may not be aware of them, and when aware of them, they may not utilize them. In Pakistan for example, 37% of PWID in one study were aware of HIV prevention programs in their city, but only 19% ever used them [@pmed.1001663-Pakistan4]. There is an urgent need to expand the provision, scope, and coverage of HIV interventions among PWID in MENA to be ahead of the growing HIV epidemics.

Conclusion {#s5f}
----------

Our study identified a large volume of HIV-related biological and behavioral data among PWID in the MENA region, including quality data that appear in the scientific literature for the first time. The in-depth analyses, the quality assessment of evidence, and the comprehensive synthesis of data facilitated, for the first time to our knowledge, a rigorous characterization of the state of the epidemic among PWID across different countries in this region.

We found robust evidence for HIV epidemics among PWID in multiple countries, most of which have emerged only recently and continue to grow. The high risk and vulnerability context suggest potential for further HIV spread. HIV surveillance among PWID must be expanded to detect and monitor these budding and growing HIV epidemics, and to inform effective HIV policy and programming. This mainly includes conducting IBBSS studies among PWID in countries where such surveys have not been conducted yet, and implementing subsequent rounds, for the provision of longitudinal data, in countries that are already developing their surveillance base. Population size estimations and mapping and ethnographic studies are also needed for a better understanding of the profile and injecting and sexual networks of PWID in MENA.

The window of opportunity to control the emerging epidemics should not be missed. HIV prevention among PWID must be made a priority for HIV/AIDS strategies in MENA; and obstacles must be addressed for the provision of comprehensive services and enabling environments for PWID [@pmed.1001663-Collumbien1]. There is need to review current HIV programs among PWID in light of the emerging epidemics, and to develop service delivery models with embedded links between community-based prevention (needle/syringe exchange programs and condom provision), HIV testing, and treatment (opioid substitution and ART). Such comprehensive approach has already proven its utility in preventing HIV transmission among PWID [@pmed.1001663-DesJarlais1]--[@pmed.1001663-vanAmeijden1], but would require better resource allocation and sufficient services in priority areas for PWID.

Prevention efforts need to prioritize those most likely to be reluctant to approach facility-based services, and those with multiple and overlapping risks. Outreach and peer education can provide a means to reach those most at risk with information and services. Access to ART should be expanded in such a region with one of the lowest ART coverage globally [@pmed.1001663-WHOUNAIDSUNICEF1]. Such expansion must address the low diagnosis rate among people living with HIV [@pmed.1001663-WHOEMRO2]. Reaching the at-risk populations even in discreet unpublicized ways would contribute positively to HIV prevention [@pmed.1001663-Mumtaz2],[@pmed.1001663-Jenkins1]. Improving HIV programming among PWID in MENA is essential not only to confront the growing HIV problem in this population group, but also to prevent the onward transmission of HIV, and the bridging of the infection to other groups as has already occurred in parts of the region.
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ART

:   antiretroviral therapy

HCV

:   hepatitis C virus

IBBSS

:   integrated bio-behavioral surveillance surveys

IQR

:   interquartile range

MENA

:   Middle East and North Africa

MSM

:   men who have sex with men

NGO

:   non-governmental organization

OPT

:   Occupied Palestinian Territories

PWID

:   people who inject drugs

pyr

:   person-years

ROB

:   risk of bias

STI

:   sexually transmitted infection

UNAIDS

:   Joint United Nations Programme on HIV/AIDS

WHO/EMRO

:   Eastern Mediterranean Regional Office of the World Health Organization
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